March 2, 2016

Mari Cantwell
Chief Deputy Director
Department of Health Care Services
Director’s Office, MS 0000
P.O. Box 997413
Sacramento, CA 95899-7413

Dear Ms. Cantwell:

This letter is to inform you that the following attachments to the Special Terms and Conditions (STCs) for California’s section 1115(a) demonstration, entitled “California Medi-Cal 2020 Demonstration” (11-W-00193/9), are approved as submitted by the state and as modified through our discussions.

- Medi-Cal (PRIME) Projects and Metrics Protocol (Attachment Q)
- PRIME Program Funding and Mechanics Protocol (Attachment II)

CMS finds these protocols to be in accordance with the STCs for the demonstration, and has no further questions or comments at this time.

Copies of the approved attachments are enclosed. They will replace the corresponding attachments in the STCs.

We look forward to continuing to work with you and your staff on the California Medi-Cal 2020 Demonstration. If you have any questions, please contact your project officers, Ms. Mehreen Hossain, at either 410-786-0938 or by email at Mehreen.Hossain@cms.hhs.gov, and Ms. Heather Ross, at either 410-786-3666 or by email at Heather.Ross@cms.hhs.gov.

We appreciate your cooperation throughout the review process.

Sincerely,

/s/
Angela D. Garner
Director Division of System Reform Demonstrations

Enclosure

cc: Henrietta Sam-Louie, Acting ARA Region IX
Attachment Q - PRIME Projects and Metrics Protocol

I. Table of Contents

II. Preface ............................................................................................................................................................................. 3
   A. Public Hospital Redesign and Incentives in Medi-Cal ................................................................................................. 3
   B. PRIME Protocols ......................................................................................................................................................... 3

III. Background ...................................................................................................................................................................... 3
   A. Overview of the PRIME Program & Participating Entities ............................................................................................. 3
   B. Development Summary .................................................................................................................................................... 4

IV. Projects ........................................................................................................................................................................... 4
   A. Domains ........................................................................................................................................................................... 4
      Table 1: High-Level Summary of Projects by Domain .................................................................................................. 5
   B. Project Selection Exclusions ........................................................................................................................................ 6

V. Metrics ............................................................................................................................................................................... 6
   A. Reporting of PRIME Project Metrics ............................................................................................................................ 6
   B. Metric Types .................................................................................................................................................................. 6
      Table 2: Summary of Metric Progression from P4R to P4P ......................................................................................... 7
   C. Metrics Governance ....................................................................................................................................................... 7
   D. Innovative Metric Testing ............................................................................................................................................... 7
   E. Metrics Summary ........................................................................................................................................................... 12
      Table 2: High-Level Summary of Metrics .................................................................................................................. 12
   F. Measurement Period .................................................................................................................................................. 18
      Table 3: Measurement Periods ....................................................................................................................................... 18
   G. DMPH Infrastructure Building .................................................................................................................................. 18
   H. Establishing Baseline Performance During PRIME .................................................................................................... 18
   I. Target Setting for Pay-for-Performance Metrics ......................................................................................................... 19
   J. Minimum Number of Cases .......................................................................................................................................... 19
   K. Sampling .................................................................................................................................................................... 20
      1. Indication for Use of Sampling .................................................................................................................................. 20
   L. Defining the Denominator ........................................................................................................................................... 20

California Medi-Cal 2020 Demonstration
Approved December 30, 2015 through December 31, 2020
Amended March 2, 2016
VI. Project Toolkit ........................................................................................................................................... 21

A. Domain 1: Outpatient Delivery System Transformation and Prevention ................................................ 22
  1. Project 1.1 Integration of Behavioral Health and Primary Care ............................................................ 23
  2. Project 1.2 Ambulatory Care Redesign: Primary Care ......................................................................... 27
  3. Project 1.3 Ambulatory Care Redesign: Specialty Care ..................................................................... 31
  4. Project 1.4 Patient Safety in the Ambulatory Setting ......................................................................... 35
  5. Project 1.5 Million Hearts Initiative ................................................................................................... 37
  6. Project 1.6 Cancer Screening and Follow-up ....................................................................................... 40
  7. Project 1.7 Obesity Prevention and Healthier Foods Initiative .......................................................... 43

B. Domain 2: Targeted High-Risk or High-Cost Populations .................................................................... 45
  1. Project 2.1 Improvements in Perinatal Care ........................................................................................ 46
  2. Project 2.2 Care Transitions: Integration of Post-Acute Care ............................................................... 49
  3. Project 2.3 Complex Care Management for High Risk Medical Populations ..................................... 52
  4. Project 2.4 Integrated Health Home for Foster Children ................................................................... 55
  5. Project 2.5 Transition to Integrated Care: Post Incarceration ............................................................... 58
  6. Project 2.6 Chronic Non-Malignant Pain Management ..................................................................... 61
  7. Project 2.7 Comprehensive Advanced Illness Planning and Care ......................................................... 65

C. Domain 3: Resource Utilization Efficiency ........................................................................................... 68
  1. Project 3.1 Antibiotic Stewardship ........................................................................................................ 69
  2. Project 3.2 Resource Stewardship: High-Cost Imaging ..................................................................... 72
  3. Project 3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals ....................... 74
  4. Project 3.4 Resource Stewardship: Blood Products .......................................................................... 77
II. Preface

A. Public Hospital Redesign and Incentives in Medi-Cal
On December 30, 2015, the Centers for Medicare and Medicaid Services (CMS) approved California’s request for a renewal to California’s section 1115(a) Medicaid demonstration (hereinafter “demonstration”) authorizing the creation of a Public Hospital Redesign and Incentives in Medi-Cal (hereinafter “PRIME”).

B. PRIME Protocols
The PRIME requirements specified in the STCs are supplemented by the following attachments to the STCs:

Attachment D. Designated Public Hospital Systems and District/Municipal Public Hospitals that are Participating PRIME entities

Attachment Q. PRIME Projects and Metrics (this document): This Attachment details the specific delivery system improvement activities (“projects”), including requirements regarding project metrics, that are eligible for PRIME funding; for each project, Attachment Q specifies the details of the projects, projects’ metrics, and metrics’ targets that will be the basis for earning PRIME incentive payments. Attachment Q also specifies the key elements of and the review and approval process for participating PRIME entities’ 5-year PRIME Project Plans. Participating PRIME entities will utilize this document for purposes of selecting projects (each of which specifies required metrics) to include in their 5-year PRIME Project Plans.

Attachment R. Alternative Payment Methodologies: Attachment R will outline additional payment methodologies that will qualify as APM outside of the capitation payment methodologies.

Attachment S. PRIME Evaluation and Monitoring: Attachment S will describe the state’s plan for meeting PRIME monitoring requirements as well as will include the final evaluation plan.

Attachment II. PRIME Funding and Mechanics: Attachment II describes the general requirements for receiving incentive payments under PRIME, including the allocation, payment mechanisms and disbursement of pool funds; reporting requirements; and reinvestment of unallocated funds.

III. Background

A. Overview of the PRIME Program & Participating Entities
The Public Hospital Redesign and Incentives in Medi-Cal (PRIME) Pool will build upon the foundational delivery system transformation work, expansion of coverage, and increased access to coordinated primary care achieved through the prior California Section 1115 Bridge to Reform demonstration. The activities supported by the PRIME Pool are designed to accelerate efforts by participating PRIME entities (as defined in Attachment D) to change care delivery to maximize health care value and strengthen their ability to successfully perform under risk-based alternative payment models (APMs) in the long term, consistent with CMS and Medi-Cal 2020 goals. The PRIME program is intentionally designed to be ambitious in scope and time-limited. Using evidence-based, quality improvement methods, the initial work will require the establishment of performance
baselines followed by target setting and the implementation and ongoing evaluation of quality improvement interventions. Participating PRIME entities will consist of two types of entities: Designated Public Hospital (DPH) systems and the District/Municipal Public Hospitals (DMPH) (described further in Attachment II).

DPHs participating in PRIME, will be required to contract with at least one Medi-Cal Managed Care Provider (MCP) in the MCP service area that they operate using APM methodologies as part of their PRIME Project Plan by January 1, 2018. If a DPH is unable to meet this requirement and can demonstrate that it has made a good faith effort to contract with an MCP in the service area that it operates in and a gap in contract period occurs, DHCS has discretion to waive this requirement as specified in Attachment R.

Each project in PRIME has a required set of projects and metrics in which payment will be tied to performance. Domains, projects and metrics are described below in more detail.

B. Development Summary
PRIME projects have been identified and designed through a rigorous, lengthy, thoughtful and consultative process. Every project and each metric has gone through a thorough, iterative process based on detailed criteria over the past year and a half that included in-depth review by and input from:

- Over 100 clinical and quality experts with on-the-ground experience caring for California’s Medi-Cal beneficiaries and most vulnerable populations,
- Experts on reporting/IT technical capabilities of the public hospital safety net that have a deep working knowledge of Medi-Cal data and state reporting,
- Public hospital leadership across the state,
- Quality improvement professionals in partnership with DHCS, and
- Public stakeholder representing statewide health care, consumer and advocacy organizations

Each project is measured by a core required set of metrics so that all participating PRIME entities are working toward industry best practices and the same desired results; as such, the program will yield comparable data across entities and throughout the Demonstration. The data to be reported through the PRIME will be meaningful and provide useful information in order to continue to drive improvement.

IV. Projects
A. Domains
Projects are organized into 3 domains. Participating DPH systems will implement at least 9 PRIME projects, and participating DMPHs will implement at least one PRIME project, as part of the participating PRIME entity’s Five-year PRIME Plan. Participating DPH systems must select at least four Domain 1 projects (three of which are specifically required), at least four Domain 2 projects (three of which are specifically required), and at least one Domain 3 project.
The projects by domain are summarized in Table 1 below.

**Table 1: High-Level Summary of Projects by Domain**

<table>
<thead>
<tr>
<th>Domain Name</th>
<th>Required Projects by Domain for DPHs</th>
<th>Project(s)</th>
<th>Required for DPHs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domain 1: Outpatient Delivery System Transformation and Prevention</td>
<td>3 required projects + 1 additional</td>
<td>Project 1.1 Integration of Physical and Behavioral Health</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.2 Ambulatory Care Redesign: Primary Care (includes reduction in disparities in health and health outcomes)</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.3 Ambulatory Care Redesign: Specialty Care</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.4 Patient Safety in the Ambulatory Setting</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.5 Million Hearts Initiative</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.6 Cancer Screening and Follow-up</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 1.7 Obesity Prevention and Healthier Foods Initiative</td>
<td>N</td>
</tr>
<tr>
<td>Domain 2: Targeted High Risk or High Cost Populations</td>
<td>3 required projects + 1 additional</td>
<td>Project 2.1 Improved Perinatal Care</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.2 Care Transitions: Integration of Post-Acute Care</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.3 Complex Care Management for High Risk Medical Populations</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.4 Integrated Health Home for Foster Children</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.5 Transition to Integrated Care: Post Incarceration</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.6 Chronic Non-Malignant Pain Management</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 2.7 Comprehensive Advanced Illness Planning and Care</td>
<td>N</td>
</tr>
<tr>
<td>Domain 3: Resource Utilization Efficiency</td>
<td>1 minimum</td>
<td>Project 3.1 Antibiotic Stewardship</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 3.2 Resource Stewardship: High Cost Imaging</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 3.3 Resource Stewardship: Therapies Involving High Cost Pharmaceuticals</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project 3.4 Resource Stewardship: Blood Products</td>
<td>N</td>
</tr>
</tbody>
</table>
Descriptions of each project can be found below in Section VI.

B. Project Selection Exclusions
Participating PRIME entities may only select projects for which the target population is sufficient to accurately measure success, as defined as having greater than or equal to 30 individuals meeting the project target population definition. Participating PRIME entities also may not select optional projects for which they have achieved top performance of the metric benchmark for > 50% of the number of a project’s metrics. If a DPH is unable to select a particular optional project for the above reason, the DPH must choose another optional project from the same domain as necessary to fulfill program minimum project requirements. If a DPH is unable to select a particular required project for either of the above reasons, the DPH must choose another project from the same domain as necessary to fulfill program minimum project requirements.

V. Metrics

A. Reporting of PRIME Project Metrics
Reporting of metrics will be completed per the Program Funding and Mechanics Protocol (Attachment II, Section VII). Participating PRIME entities will report on all metrics required for each project, unless as described by Section IV.B. All PRIME metric reporting will conform to technical measure specifications as required by DHCS. Each participating PRIME entity will receive PRIME incentive payments based on the participating PRIME entity’s performance on the project metrics, per Attachment II.

Each project has a required set of metrics. Section V.E lists the specific metrics that will be used to assess performance. All metrics are reported at the DPH or DMPH level.

B. Metric Types
1. Metrics are primarily clinical metrics.
2. Metrics were chosen from State, Medi-Cal, or CMS quality metrics if available.
3. Metrics were preferentially chosen from state or national metrics which have been vetted by Measure Stewards, which are defined as recognized, authoritative entities able to assess clinical relevance, feasibility and appropriateness of a metric. Examples of Measure Stewards include the NCQA, AMA, and CMS. These vetted measures have been included in PRIME as “standard metrics” where possible. Innovative metrics, representing around 20% of all metrics, are used to measure performance for PRIME projects only in instances in which a project’s current set of standard metrics does not adequately assess successful transformation. Innovative metrics are defined as metrics that, at the beginning of PRIME, have not yet undergone a vetting and testing process by a Measure Steward. Measure Stewards have been identified for every innovative metric. Innovative metrics enable participating PRIME entities to demonstrate the transformation of health care towards coordinated, team-based, patient-centered care, in a manner not afforded by many of the standard metrics. Innovative metrics will go through an established metric testing process, as described in the DHCS PRIME Metrics and Specification Manual.
4. Pay for Reporting and Pay for Performance: Following the submission of baseline data for all metrics in DY 11, the majority of standard metrics will convert to pay-for-performance in DY 12. A smaller proportion of standard metrics, those which are both new to participating PRIME entities and are much more complex to report on, will convert to pay-for-performance in DY 13. The innovative metrics will convert to pay-for-performance in later years once each has completed a rigorous testing process as described in the Innovative Metric Testing summary found in D. Table 2 provides a breakdown of the transition of PRIME metrics from pay-for-reporting to pay-for-performance for each DY.

Table 2: Summary of Metric Progression from P4R to P4P

<table>
<thead>
<tr>
<th></th>
<th>DY 11</th>
<th>DY 12</th>
<th>DY 13</th>
<th>DY 14</th>
<th>DY 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of P4R Metrics</td>
<td>100%</td>
<td>40%</td>
<td>21%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>% of P4P Metrics</td>
<td>0%</td>
<td>60%</td>
<td>79%</td>
<td>98%</td>
<td>98%</td>
</tr>
</tbody>
</table>

C. Metrics Governance
The measurement specifications for a PRIME metric will stay current with those of the Measure Steward and/or endorsing body. DHCS will monitor any changes to NQF-endorsed and non-NQF endorsed measures that are used in PRIME projects. If a measure is dropped or significantly changed by the measure steward, any changes will be effective at the start of the next annual PRIME Demonstration Year. Per Metric Modification Process (Attachment II, VI, C), DHCS retains authority to modify metric specifications for the program.

D. Innovative Metric Testing
Innovative metrics, are defined as metrics that at the start of PRIME have not yet undergone a vetting a testing process by a Measure Steward. All PRIME innovative metrics have a confirmed Measure Steward and will go through a formal and rigorous testing process by a DHCS PRIME Metric Technical Advisory Committee (MTAC). The Committee will test the metric against criteria including, but not limited to, importance, scientific feasibility, and usefulness as supported by evidence gathered by the Measure Steward. During the testing process, innovative metrics are pay-for-reporting until which time they have been sufficiently vetted to be pay-for-performance metrics as determined by DHCS and the above referenced metric testing process.

1. Principles Of The Process
   a. An innovative metric is a metric that currently has no state or national metric steward or entity that has already defined and vetted the metric.
   b. An innovative metric is included only when a project’s current metric set does not adequately assess successful transformation.
   c. Each PRIME innovative metric will have either DHCS or a PHS volunteering to serve as the measure steward for the duration of PRIME.
i. The measure steward is responsible for defining the specifications and providing evidence for its use.

ii. The measure steward will also recommend a reasonable high performance level based on research of evidence.

d. A in collaboration with DHCS a MTAC will govern the innovative metric testing process by which the measure will be tested against criteria including, but not limited to, importance, scientific feasibility, and usefulness as supported by evidence gathered by the measure steward.

   i. The metric will be removed from PRIME if it fails to meet test criteria.

e. Testing, refinement, and baseline setting will occur over the first three years of PRIME during which the measure maintains Pay for Reporting (P4R) status.

f. MTAC will also review the reported data to test the measure for room for improvement and stability.

g. Once MTAC has vetted the metric, MTAC will recommend to DHCS to convert the status of the metric from P4R to Pay for Performance (P4P) for the last two years of PRIME.

   i. For metrics that convert from P4R to P4P, DHCS will work with MTAC to establish improvement metrics for the final two years of the demonstration.

   ii. On an exception basis, MTAC may recommend to maintain a metric’s status as P4R status beyond the first three years based on the progress of testing.

2. **Purpose**

This PRIME Innovative Metrics Testing Process is how “innovative” measures will be defined and tested for appropriate inclusion in PRIME. An innovative measure (formerly referred to as “novel”) is a measure that currently has no state or national measure steward or entity that has already defined and vetted the measure. Innovative measures will be initially included in PRIME as P4R measures and may evolve to P4P through 5 years of the program depending on the outcomes of the Metric Testing Process.

1. **Role Of The Measure Steward**

   a. Draft the measure specifications, including:

      i. The “narrative” version of the specifications

         1. [Here is an example](#) of measure specs that include both the “narrative” version and the electronic specs (aka eCQM – electronic Clinical Quality Measurement Standard)
Metric). While we might not need all the rationale and background that is in that document, we certainly need all the specifics.

ii. Measurement period

iii. Numerator/Denominator

iv. Exclusions & exceptions

v. Methodologies for any needed calculations

vi. Data criteria, including data sources and codes needed for reporting (i.e., when your IT/Data/Business Intelligence Dept asks you for details so they can develop the query and reports)

b. Gathering evidence supporting the measure’s fulfillment of the evaluation criteria as described below.

c. In conjunction with the MTAC, determine if and when the metric is “stable” enough with sufficient data to move from testing (P4R) to financial accountability (P4P.)

d. Serve as the content expert resource body for the measure in conjunction with the Metric Technical Advisory Committee (MTAC) for technical expertise

   i. Answer any questions that will come back from PHS using the metric

   ii. Revise the measure specifications as issues arise

2. Role Of MTAC

   a. Composed of clinical, operational, and reporting/technical experts, MTAC will govern the testing process

   b. Test the metric specifications and ask for additional clarification from measure steward

      i. Is this information adequate for reporting at my system?

      ii. What additional information needs to be provided to ensure standardized reporting?

      iii. Other questions as they see fit

   c. Evaluate the measure (via the Worksheet completed by the Measure Steward) against test criteria:

      i. Importance – clinical impact to PRIME project target population
ii. Scientific acceptability – measure is evidence-based, reliable, valid, and precise

iii. Feasibility – data for the measure can be collected without undue burden;, data is auditable

iv. Usefulness – results in useful information to stakeholders; applicability to a significant population, robust results for public reporting

v. Room for improvement – based on available evidence, Measure Steward determines what would reasonably be considered high performance for this measure. MTAC, in conjunction with the Measure Steward will assess data, obtained during the testing period, against the high performance benchmark identified by the Measure Steward to determine room for improvement across the PHS.

d. Serve as the technical resource body for the measure along with the Measure Steward.

3. **Process Steps**

<table>
<thead>
<tr>
<th>Responsible Entity</th>
<th>Step</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure Steward</td>
<td>Completes the PRIME Innovation Metric Worksheet with measure specifications and supporting evidence.</td>
<td>Q1 2016</td>
</tr>
<tr>
<td>MTAC</td>
<td>Reviews the worksheet and conceptually tests the measure according to test criteria.</td>
<td>Q2 2016</td>
</tr>
<tr>
<td>Measure Steward</td>
<td>Refines measure specifications based on MTAC input.</td>
<td>Q2 2016</td>
</tr>
<tr>
<td>PHS</td>
<td>Mock reports on the measure, identifying reporting issues and questions.</td>
<td>Q3 2016</td>
</tr>
<tr>
<td>MTAC, Measure Steward</td>
<td>Provide additional guidance and revises measure specifications accordingly.</td>
<td>Q3 2016</td>
</tr>
<tr>
<td>Responsible Entity</td>
<td>Step</td>
<td>Timeframe</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>PHS</td>
<td>Collect baseline data and reports to MTAC.</td>
<td>Q3-Q4 2016</td>
</tr>
<tr>
<td>MTAC, Measure Steward</td>
<td>Test the collected data for room for improvement against the high performance level as identified by the Measure Steward. If there is no room for improvement, then the measure is dropped.</td>
<td>Q3 2016</td>
</tr>
<tr>
<td>PHS</td>
<td>Relay any issues or concerns about each innovative metric to MTAC.</td>
<td>Throughout DY 12 (7/16-6/17)</td>
</tr>
<tr>
<td>MTAC, MS</td>
<td>Revise measure specification or provide additional guidance as needed based on ongoing feedback.</td>
<td>Throughout DY 12</td>
</tr>
<tr>
<td>MTAC</td>
<td>Review PHS-reported data and feedback for each innovative measure to decide whether the P4R P4P status conversion should deviate from the original timetable (see below).</td>
<td>After DY 12 Annual report</td>
</tr>
<tr>
<td>PHS</td>
<td>Collect and report on measure, relaying issues or concerns that arise.</td>
<td>DY 13*</td>
</tr>
<tr>
<td>MTAC</td>
<td>Reviews PHS-reported data and feedback for each innovative measure. Revises if needed. Determines high performance level and performance target methodology.</td>
<td>After DY 13 Annual report</td>
</tr>
<tr>
<td>MTAC</td>
<td>Approves final measure specifications and recommends DHCS submit to CMS for approval of conversion to P4P.</td>
<td>After DY 13 Annual Report</td>
</tr>
<tr>
<td>DHCS</td>
<td>DHCS submits to CMS for approval of measure as P4P.</td>
<td>Q3 2017</td>
</tr>
<tr>
<td>Responsible Entity</td>
<td>Step</td>
<td>Timeframe</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>CMS</td>
<td>Approve measure for P4P.</td>
<td>Q4 2017</td>
</tr>
<tr>
<td>PHS</td>
<td>Report on measure, relaying technical issues and questions to MTAC as needed.</td>
<td>DY 14 and 15</td>
</tr>
</tbody>
</table>

* PHS get paid for reporting on the measure at the time of the Annual Report even if the measure hasn't completed the entire testing process yet and achieved stability.

4. **P4R/P4P Timeline**

In general, an innovative measure will be P4R in Year 1, 2, and 3; P4P in Year 4, and 5 as the metric is defined as stable and testing is complete.

E. **Metrics Summary**

The metrics by project are summarized in Table 2 below.

**Table 2: High-Level Summary of Metrics**

<table>
<thead>
<tr>
<th>Table 2: Measure name</th>
<th>Projects Numbers Associated with Measure (DPH Required Projects underlined)</th>
<th>Measure Steward Innovative metrics marked by *</th>
<th>NQF#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal Results Follow-Up</td>
<td>1.4</td>
<td>*Alameda Health System (AHS)</td>
<td>N/A</td>
</tr>
<tr>
<td>Adherence to Medications</td>
<td>3.3</td>
<td>*AHS, Santa Clara Valley Health System</td>
<td></td>
</tr>
<tr>
<td>Adolescent Well-Care Visit</td>
<td>2.4</td>
<td>NCQA</td>
<td>N/A</td>
</tr>
<tr>
<td>Advance Care Plan</td>
<td>2.7</td>
<td>NCQA</td>
<td>0326</td>
</tr>
<tr>
<td>Alcohol and Drug Misuse (SBIRT)</td>
<td>1.1, 1.2, 2.5, 2.6</td>
<td>Oregon CCO</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Name</td>
<td>Projects Numbers Associated with Measure (DPH Required Projects underlined)</td>
<td>Measure Steward Innovative metrics marked by *</td>
<td>NQF#</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Ambulatory Palliative Care Team Established</td>
<td>2.7¹</td>
<td>*UC San Francisco (UCSF)</td>
<td>N/A</td>
</tr>
<tr>
<td>Annual Monitoring for Patients on Persistent Medications</td>
<td>1.4</td>
<td>NCQA</td>
<td>2371</td>
</tr>
<tr>
<td>Assessment and Management of Chronic Pain: Patients with chronic pain prescribed an opioid who have an opioid agreement form and an annual urine toxicology screen</td>
<td>2.6</td>
<td>AHRQ</td>
<td>N/A</td>
</tr>
<tr>
<td>Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis</td>
<td>3.1</td>
<td>NCQA</td>
<td>0058</td>
</tr>
<tr>
<td>Avoidance of Antibiotic Treatment with Low Colony Urinary Cultures</td>
<td>3.1</td>
<td>*University of California Davis (UCD), UC Irvine (UCI), UC San Diego (UCSD)</td>
<td>N/A</td>
</tr>
<tr>
<td>Baby Friendly Hospital designation</td>
<td>2.1</td>
<td>Baby-Friendly USA/DHCS</td>
<td>N/A</td>
</tr>
<tr>
<td>BIRADS to Biopsy</td>
<td>1.6</td>
<td>*LA County Dept of Health Services (LAC DHS), San Francisco Health Network (SFHN)</td>
<td>N/A</td>
</tr>
<tr>
<td>BMI Screening and Follow-up</td>
<td>1.7</td>
<td>CMS</td>
<td>0421</td>
</tr>
<tr>
<td>Breast Cancer Screening</td>
<td>1.6</td>
<td>NCQA</td>
<td>2372</td>
</tr>
<tr>
<td>Care Coordinator Assignment</td>
<td>1.1, 2.3</td>
<td>University of Washington/Coordinated Care Initiative</td>
<td>N/A</td>
</tr>
<tr>
<td>Cervical Cancer Screening</td>
<td>1.6</td>
<td>NCQA</td>
<td>0032</td>
</tr>
<tr>
<td>CG-CAHPS: Provider Rating</td>
<td>1.2</td>
<td>AHRQ</td>
<td>0005</td>
</tr>
<tr>
<td>Closing the referral loop: receipt of specialist report (CMS50v3)</td>
<td>1.3</td>
<td>CMS</td>
<td>N/A</td>
</tr>
<tr>
<td>Colorectal Cancer Screening</td>
<td>1.2, 1.6</td>
<td>NCQA</td>
<td>0034</td>
</tr>
<tr>
<td>Comprehensive Diabetes Care:</td>
<td>1.1, 1.2</td>
<td>NCQA</td>
<td>0059</td>
</tr>
</tbody>
</table>

¹ The “Ambulatory Palliative Care Team Established” metric will start in DY11 and sunset once the PRIME Entity can attest to the establishment of their Ambulatory Palliative Care Team. This metric works in tandem with the metric “Palliative Care Service Offered at Time of Diagnosis of Advanced Illness”.

---

California Medi-Cal 2020 Demonstration
Approved December 30, 2015 through December 31, 2020
Ammended March 2, 2016
<table>
<thead>
<tr>
<th>Measure Name</th>
<th>Projects Numbers Associated with Measure (DPH Required Projects underlined)</th>
<th>Measure Steward</th>
<th>Innov. metrics marked by</th>
<th>NQF#</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c Poor Control (&gt;9.0%)</td>
<td></td>
<td>NCQA</td>
<td></td>
<td>0018</td>
</tr>
<tr>
<td>Controlling Blood Pressure</td>
<td>1.2, 1.5, 2.5</td>
<td>NCQA</td>
<td></td>
<td>0710</td>
</tr>
<tr>
<td>Depression Remission at 12 Months (CMS159v4)</td>
<td>1.1</td>
<td>Minnesota Community Measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developmental Screening in the First Three Years of Life</td>
<td>2.4</td>
<td>NCQA</td>
<td></td>
<td>1448</td>
</tr>
<tr>
<td>DHCS All-Cause Readmissions</td>
<td>1.3, 2.2</td>
<td>CDHCS</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Documentation of Current Medications in the Medical Record</td>
<td>3.3</td>
<td>CMS</td>
<td></td>
<td>0419</td>
</tr>
<tr>
<td>Documentation of Current Medications in the Medical Record (0-18 yo)</td>
<td>2.4</td>
<td>CMS</td>
<td>Variation on 0419</td>
<td></td>
</tr>
<tr>
<td>Documented REAL and/or SO/GI disparity reduction plan</td>
<td>1.2 2</td>
<td>DHCS</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>ePBM-01 Pre-op Anemia Screening, Selected Elective Surgical Patients</td>
<td>3.4</td>
<td>AABB/TJC (approval pending)</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>ePBM-02 Pre-op Hemoglobin Level, Selected Elective Surgical Patients</td>
<td>3.4</td>
<td>AABB/TJC (approval pending)</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>ePBM-03 Pre-op Type and Crossmatch, Type and Screen, Selected Elective Surgical Patients</td>
<td>3.4</td>
<td>AABB/TJC (approval pending)</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>ePBM-04 Initial Transfusion Threshold</td>
<td>3.4</td>
<td>AABB/TJC (approval pending)</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>ePBM-05 Outcome of Patient Blood Management, Selected Elective Surgical Patients</td>
<td>3.4</td>
<td>AABB/TJC (approval pending)</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Exclusive Breast Milk Feeding (PC-05)</td>
<td>2.1</td>
<td>JNC</td>
<td></td>
<td>0480</td>
</tr>
<tr>
<td>H-CAHPS: Care Transition Metrics (3)</td>
<td>2.2</td>
<td>AHRQ</td>
<td></td>
<td>0166</td>
</tr>
<tr>
<td>High-Cost Pharmaceuticals Ordering Protocols</td>
<td>3.3</td>
<td>*AHS</td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>

2 The “Documented REAL and/or SO/GI disparity reduction plan” metric will only be active for DY 12.
<table>
<thead>
<tr>
<th>Table 2: Measure name</th>
<th>Projects Numbers Associated with Measure (DPH Required Projects underlined)</th>
<th>Measure Steward Innovative metrics marked by *</th>
<th>NQF#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging for Routine Headaches (Choosing Wisely)</td>
<td>3.2</td>
<td>*Washington Health Alliance</td>
<td>N/A</td>
</tr>
<tr>
<td>Inappropriate Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism</td>
<td>3.2</td>
<td>ACEP</td>
<td>0667</td>
</tr>
<tr>
<td>Influenza Immunization</td>
<td>1.3</td>
<td>NCQA</td>
<td>0041</td>
</tr>
<tr>
<td>INR Monitoring for Individuals on Warfarin</td>
<td>1.4</td>
<td>CMS</td>
<td>0555</td>
</tr>
<tr>
<td>Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</td>
<td>1.2, 1.5</td>
<td>NCQA</td>
<td>0068</td>
</tr>
<tr>
<td>Medication Reconciliation – 30 days</td>
<td>2.2, 2.3</td>
<td>NCQA</td>
<td>0097</td>
</tr>
<tr>
<td>MWM #8: Treatment Preferences (documentation) Inpatient</td>
<td>2.7</td>
<td>UNC Chapel Hill</td>
<td>1641</td>
</tr>
<tr>
<td>MWM #8: Treatment Preferences (documentation) Outpatient</td>
<td>2.7</td>
<td>*UCSF</td>
<td>N/A</td>
</tr>
<tr>
<td>National Healthcare Safety Network (NHSN) Antimicrobial Use Measure</td>
<td>3.1</td>
<td>CDC</td>
<td>2720</td>
</tr>
<tr>
<td>OB Hemorrhage: Massive Transfusion</td>
<td>2.1</td>
<td>CMQCC</td>
<td>N/A</td>
</tr>
<tr>
<td>OB Hemorrhage: Total Products Transfused</td>
<td>2.1</td>
<td>CMQCC</td>
<td>N/A</td>
</tr>
<tr>
<td>Palliative Care Service Offered at Time of Diagnosis of Advanced Illness</td>
<td>2.7³</td>
<td>*University of California, San Francisco (UCSF)</td>
<td>N/A</td>
</tr>
<tr>
<td>Partnership for a Healthier America's Hospital Health Food Initiative external food service verification</td>
<td>1.7</td>
<td>DHCS</td>
<td>N/A</td>
</tr>
<tr>
<td>Patients with chronic pain on</td>
<td>2.6</td>
<td>*AHRQ/SFHN, AHS, UCSD</td>
<td>N/A</td>
</tr>
</tbody>
</table>

³ The “Palliative Care Service Offered at Time of Diagnosis of Advanced Illness” metric will be reported as P4R the same Demonstration Year that the PRIME Entity can attest to the establishment of their Ambulatory Palliative Care Team. For the remaining Demonstration Years the “Palliative Care Service Offered…” will be P4P.
### Table 2: Measure name

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>Projects Numbers Associated with Measure (DPH Required Projects underlined)</th>
<th>Measure Steward Innovative metrics marked by *</th>
<th>NQF#</th>
</tr>
</thead>
<tbody>
<tr>
<td>long term opioid therapy checked in PDMPs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC-02 Cesarean Section</td>
<td>2.1</td>
<td>JNC</td>
<td>0471</td>
</tr>
<tr>
<td>Post Procedure ED Visits</td>
<td>1.3</td>
<td>*SFHN</td>
<td>N/A</td>
</tr>
<tr>
<td>PQRS # 317 Preventative Care and Screening: Screening for High Blood Pressure and Follow-Up Documented</td>
<td>1.5</td>
<td>CMS</td>
<td>N/A</td>
</tr>
<tr>
<td>Prenatal and Postpartum Care</td>
<td>2.1</td>
<td>NCQA</td>
<td>1517</td>
</tr>
<tr>
<td>Prevention Quality Overall Composite #90</td>
<td>1.2, 2.3, 2.5</td>
<td>AHRQ</td>
<td>N/A</td>
</tr>
<tr>
<td>Primary Care Redesign metrics stratified by REAL categories and SO/GI</td>
<td>1.2</td>
<td>*DHCS</td>
<td>N/A</td>
</tr>
<tr>
<td>Prophylactic antibiotics discontinued at time of surgical closure</td>
<td>3.1</td>
<td>CMS</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion Admitted to Hospice for Less Than 3 Days</td>
<td>2.7</td>
<td>ASCO</td>
<td>0216</td>
</tr>
<tr>
<td>REAL and/or SO/GI disparity reduction</td>
<td>1.2⁴</td>
<td>*DHCS</td>
<td>N/A</td>
</tr>
<tr>
<td>REAL data completeness</td>
<td>1.2⁵</td>
<td>CMS</td>
<td>N/A</td>
</tr>
<tr>
<td>Receipt of appropriate follow-up for abnormal CRC screening</td>
<td>1.6</td>
<td>*SFHN</td>
<td>N/A</td>
</tr>
<tr>
<td>Reconciled Medication List Received by Discharged Patients</td>
<td>2.2</td>
<td>AMA-PCPI</td>
<td>0646</td>
</tr>
<tr>
<td>Reduction in Hospital Acquired Clostridium Difficile Infections</td>
<td>3.1</td>
<td>NHSN</td>
<td>N/A</td>
</tr>
<tr>
<td>Referral Reply Turnaround Rate</td>
<td>1.3</td>
<td>*LAC DHS, SFHN</td>
<td>N/A</td>
</tr>
<tr>
<td>Screening for Clinical Depression and follow-up</td>
<td>1.1, 1.2, 2.4, 2.5, 2.6</td>
<td>CMS</td>
<td>0418</td>
</tr>
<tr>
<td>Severe Maternal Morbidity (SMM) per 100 women with</td>
<td>2.1</td>
<td>CMQCC</td>
<td>N/A</td>
</tr>
</tbody>
</table>

⁴ The “REAL and/or SO/GI disparity reduction” metric will be active DY 13-15, and will be P4P throughout those years.

⁵ The “REAL data completeness” metric will be P4R in DY 11 and P4P in DY 12-15. Although this metric is active for all 5 years, it’s status is included here for the sake of clarity.
<table>
<thead>
<tr>
<th>Measure name</th>
<th>Projects Numbers Associated with Measure (DPH Required Projects underlined)</th>
<th>Measure Steward</th>
<th>Innovative metrics marked by *</th>
<th>NQF#</th>
</tr>
</thead>
<tbody>
<tr>
<td>obstetric hemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO/GI data completeness</td>
<td>1.2&lt;sup&gt;6&lt;/sup&gt;</td>
<td>CMS</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Specialty Care Touches: Specialty Expertise Requests Managed Via Non-Face to Face Specialty Encounters</td>
<td>1.3</td>
<td>*LAC DHS, UCD</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Timely Transmission of Transition Record</td>
<td>2.2, 2.3</td>
<td>AMA-PCPI</td>
<td>0648</td>
<td></td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling</td>
<td>1.1, 1.2, 1.3, 1.5, 2.5</td>
<td>AMA-PCPI</td>
<td>0028</td>
<td></td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling (13 yo and older)</td>
<td>2.4</td>
<td>AMA-PCPI</td>
<td>Variation on 0028</td>
<td></td>
</tr>
<tr>
<td>Treatment of Chronic Non-Malignant Pain with Multi-Modal Therapy</td>
<td>2.6</td>
<td>*SFHN, AHS, UCSD</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Unexpected Newborn Complications (UNC)</td>
<td>2.1</td>
<td>California Maternal Quality Care Collaborative (CMQCC)</td>
<td>0716</td>
<td></td>
</tr>
<tr>
<td>Use of Imaging Studies for Low Back Pain</td>
<td>3.2</td>
<td>NCQA</td>
<td>0052</td>
<td></td>
</tr>
<tr>
<td>Use of Imaging Studies for Low Back Pain (red flags, no time limit)</td>
<td>3.2</td>
<td>*LAC Department of Health Services</td>
<td>Variation on NQF 0052</td>
<td></td>
</tr>
<tr>
<td>Well Child Visits - First 15 months of life</td>
<td>2.4</td>
<td>NCQA</td>
<td>1392</td>
<td></td>
</tr>
<tr>
<td>Well Child Visits - Third, Fourth, Fifth, and Sixth Years of life</td>
<td>2.4</td>
<td>NCQA</td>
<td>1516</td>
<td></td>
</tr>
<tr>
<td>Weight Assessment &amp; Counseling for Nutrition and Physical Activity for Children &amp; Adolescents</td>
<td>1.7</td>
<td>NCQA</td>
<td>0024</td>
<td></td>
</tr>
</tbody>
</table>

<sup>6</sup> The “SO/GI data completeness” metric will become active starting in DY 12 as P4R and will be P4P in DY 13-15.
Below are further details for metric measurement.

**F. Measurement Period**

Measurement periods are summarized in Table 3 below.

<table>
<thead>
<tr>
<th>Demonstration Year (DY)</th>
<th>Mid-Year Report Measurement Period</th>
<th>Mid-Year Report Due</th>
<th>Year-End Report Measurement Period</th>
<th>Year-End Report Due</th>
</tr>
</thead>
<tbody>
<tr>
<td>DY 11</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td>July 1, 2015 – June 30, 2016</td>
<td>September 30, 2016</td>
</tr>
</tbody>
</table>

**G. DMPH Infrastructure Building**

Subject to the funding limits in PRIME Funding and Mechanics (Attachment II), DHCS shall review, approve, and make payments for DMPHs in accordance with the requirements in PRIME Funding and Mechanics (Attachment II). DMPH infrastructure building payments shall be paid in accordance with PRIME Funding and Mechanics (Attachment II). DMPH infrastructure building payments shall support 1) infrastructure activities to integrate services among local entities that serve the target population; 2) services not otherwise covered or directly reimbursed by Medi-Cal to improve care for the target population; and 3) other strategies including data and related quality improvement systems, to advance integration, reduce unnecessary utilization of health care services, and improve health outcomes. Infrastructure building metrics must be reported mid-year and annually, with reporting of process pay for performance (P4P) metrics beginning no later than one year following the start of the demonstration. These metrics will allow DMPHs to establish the essential infrastructure necessary to drive healthcare system transformation. DMPHs will be able to develop a set of infrastructure building metrics that are linked to their selected project metric(s) set outlined in sections V.A-C below (Domains 1-3). The infrastructure building metrics will be included as part of DMPHs five-year PRIME Pool Plans and approved of by DHCS and CMS.

**H. Establishing Baseline Performance During PRIME**
To fulfill metric reporting for all PRIME projects for DY 11, Participating PRIME entities will submit reports on metric baseline performance, per the PRIME Program and Funding Mechanics Attachment II. The DY11 report will include baseline data for all relevant project metrics and will identify data sources, consolidating data from multiple inpatient and ambulatory systems, and including data reported from health plans.

I. Target Setting for Pay-for-Performance Metrics

By DY12, the majority of standard metrics will convert to P4P status. All metrics classified as P4P will have annual P4P targets for each of the DYs. At the beginning of each Demonstration Year, participating PRIME entities will know the annual performance target to be achieved by the end of that Demonstration Year. The method for determining the annual performance target will remain the same throughout the PRIME years for that metric. The participating PRIME entity will earn incentive payments on P4P measures proportional to the achievement value, per Program Funding and Mechanics Protocol (Attachment II).

Below are target setting methodologies for PRIME:

1. **10% Gap Closure**: This methodology will be used for metrics that have available state or national Medicaid, or other comparable populations, 90th percentile benchmarks. The gap is defined as the difference between the end of demonstration year performance and the 90th percentile benchmark. The target setting methodology will be a 10% gap closure year over year. This is the preferred methodology because top performance is defined relative to state or national top performance and targets are relative to individual performance. This methodology has been widely adopted in pay-for-performance programs across the nation.

2. **Improvement Over Self**: For those metrics without a state or national Medicaid benchmark available, including innovative metrics using pay-for-performance, DHCS will set a standard percent improvement (e.g. 10%) relative to individual current annual performance. On a metric by metric basis, DHCS will determine the percent improvement based on available evidence of what is a reasonable expectation for magnitude of clinical change. This standard relative improvement will be used by every participating PRIME entity reporting on that metric.

DHCS will set a high performance level and a minimum performance level for pay-for-performance measures. These levels will be used as guidelines to set targets. Each subsequent year, the annual target will be reset based on performance at the end of the prior year. Over the course of the PRIME, DHCS will update the high and minimum performance levels, i.e., the benchmark performance levels, as they may be revised by Metric Stewards. Any change will be effective at the start of the next annual reporting period.

J. Minimum Number of Cases

A participating PRIME entity must have a minimum of 30 individuals or cases in a metric denominator in order to be eligible to report on that metric, as determined by DHCS. If a participating PRIME entity meets this minimum, then the participating PRIME entity must report the metric. If a participating PRIME entity has
fewer than 30 cases, then the participating PRIME entity is not eligible to report on the metric for the reporting period.

**K. Sampling**

1. **Indication for Use of Sampling**

   For each measure, the participating PRIME entity has the option to either report on the entire measure population or on a sample, adhering closely to sampling criteria published and maintained in the CMS Hospital Outpatient Quality Reporting Program Specifications Manual. For each measure, participating PRIME entities are required to indicate if sampling was used when reporting performance data.

   Participating PRIME entities are encouraged to submit as many cases as possible up to the entire population of cases if reasonably feasible. If the raw data can be easily extracted from an existing electronic database or the abstraction burden is manageable, the participating PRIME entity should submit the entire population of cases that meet the initial selection criteria. Otherwise, a statistically valid sample can be selected.

   If the participating PRIME entity is not sampling, the entity should use all medical records identified in the population. If the participating PRIME entity is sampling, the entity should use the medical records from the cases in the identified sample.

   When a measure population size is less than the minimum number of cases for the sample size, sampling cannot be used, as determined by DHCS.

**L. Defining the Denominator**

The denominator for each metric is determined uniformly through a standardized process (outlined below). When reporting the baseline data for the metric, the participating PRIME entity must report to DHCS the methodology for determining the denominator in order to demonstrate uniformity with other participating PRIME entities also reporting that metric for that project. For each subsequent report on that metric, the same methodology, as approved by DHCS, must be applied for determining the population to include in the metric denominator.

Step 1) For DPHs: Determine the PRIME Defined Population composed of (a) all Medi-Cal Managed Care primary care lives assigned to the participating PRIME entity as listed by DHCS at the end of each measurement period; and (b) all individuals with at least two encounters by the participating PRIME entity for an eligible primary care service during the measurement period. This Defined Population serves as the starting point for all metric denominators, and then for each project is refined in Step 2 below.

---

7 Assigned lives must have been continuously enrolled with the participating PRIME entity during the preceding 12 months, have no gaps in enrollment greater than 45 days, and be enrolled with the participating PRIME entity on the last day of the measurement period.

8 Eligible Primary Care Services include both traditional face-to-face encounters with a provider, as well as any Complementary Service Encounter defined through the Global Payment Program for the Remaining Uninsured under this same 1115 Medicaid Waiver. See Global Payment Program Attachment EE for details.
For DMPHs: Determine the PRIME Defined Population composed of all individuals with at least two encounters by the participating PRIME entity among Medi-Cal beneficiaries. This Defined Population serves as the starting point for all metric denominators, and then for each project is refined in Step 2 below.

Step 2) Determine the Project Population. The Project Population for each project is further refined based on the focus of the project, which includes narrowing or expanding the Program Population to best align with the goals of the project.

Step 3) Determine the Metric Denominator by only including those individuals or visits from the Project Population that meet the metric measurement specifications.

VI. Project Toolkit

Each project description includes the:

- Rationale for the proposed project (evidence base and reasoning behind project idea),
- Goals and objectives of the project (project-specific Triple Aim goals and expected project outcomes),
- Core components, or key activities to guide project development and implementation, and
- Metrics required for the project, including clinical event outcomes, potentially preventable events, and patient experience measures.

The Core Components for projects are not required. However, most will be necessary to achieve the required results. The core components provide a guide for participating PRIME entities as they develop and implement the projects. In this way, the core components promote standardization across the program, while allowing participating PRIME entities to tailor program activities to meet local needs.
A. Domain 1: Outpatient Delivery System Transformation and Prevention
Projects 1.1-1.3 Required for DPHs

Projects included in Domain 1 are designed to ensure that patients experience timely access to high-quality and efficient patient-centered care. Participating PRIME entities will improve physical and behavioral health outcomes, care delivery efficiency and patient experience, by establishing or expanding fully integrated care, culturally and linguistically appropriate teams—delivering coordinated comprehensive care for the whole patient.

Primary and specialty care will be integrated and designed to work collaboratively with patients and care providers. Patients will receive appropriate preventive services, early diagnosis and treatment, and will be supported in improving their ability to care for themselves through access to other needed services including those that support social and well-being needs. Particular attention will be focused on optimizing care experience and outcomes, and improving patient safety in the outpatient setting where an increasing volume of care is being provided.

Multi-disciplinary care teams will provide coordinated care that meets the patient’s needs and preferences, and results in improved capacity for patient self-management and a reduction in avoidable acute care and interventions, thereby improving quality of life and health outcomes. Several projects in this Domain will also identify and increase rates of cost-effective standard approaches to prevention services for a select group of high-impact clinical conditions and populations (cardiovascular disease; breast, cervical and colorectal cancer; and obesity).
1. Project 1.1 Integration of Behavioral Health and Primary Care
Required Project for DPHs

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.1 Integration of Behavioral Health and Primary Care</td>
</tr>
</tbody>
</table>
| Rationale      | According to the DHCS Mental Health Prevalence Estimates, 15.9% of Californian adults suffer from Mental Health Disorder (MHD). This translates to 4.4 million Californians that are in need of mental health treatment. Nearly 2 million Californians are suffering from a serious mental illness (SMI); 4.3% and 7.4% of adults and children, respectively. A common co-occurring condition with Mental Health Disorder (MHD) is substance use disorder (SUD), which plagues 8.8% of Californians. A fragmented health care system is ill equipped to treat people with chronic medical and behavioral issues. In order to combat the gap in treatment of MHD and SUD, as of January 2014, Medi-Cal covers new services for members with mild to moderate mental health conditions, and has implemented an Alcohol Screening, Brief Intervention and Referral to Treatment (SBIRT) benefit for adults in primary care settings.

The prevalence of MHDs varies greatly by economic status. Adult members of households below 200% of the federal poverty level are 150% more likely to have a MHD than their more affluent counterparts. Among the SMI population, the disparity is even greater. Adult members of households below 200% of the federal poverty level are almost two times more likely to have a MHD than their more affluent counterparts. The prevalence of MHDs also varies greatly by race/ethnicity. Native Americans and Hispanics are the most likely to have MHDs (20%), followed by African Americans (19%), Whites (14%), and Asians (10%), who are the least likely to have MHDs. Within distinct cultures and communities of color, stigma and cultural attitudes about behavioral health have a large impact on whether individuals seek care, and adherence to care plans and will need to be a factor in designing care teams and treatment plans.

MHDs and SUDs reduce a person’s life expectancy by 10 to 25 years, which is equivalent to the reduced life expectancy that is the result of heavy smoking. People with a MHD and/or SUD die from the same causes as does the general population, such as: heart disease, diabetes, and cancer. However, these diseases are more prevalent among people who suffer from a MHD or SUD, and lead to earlier death. For the entire population, the greatest indicators for such diseases are: smoking, obesity, hypertension, poor diet, and low levels of physical activity. Such health risks have an increased prevalence among those with a MHD and/or SUD, and have an earlier onset.

---

Because of the low rate of preventive and treatment services offered to people with a MHD and/or SUD, these individuals experience serious health burdens and are at risk of premature death.\(^{12}\) The Substance Abuse and Mental Health Services Administration and Health Resources Services Administration’s jointly funded Center for Integrated Health Solutions (SAMHSA-HRSA CIHS) advocates that the solution to providing better care to those with co-occurring conditions, whether medical or behavioral, is to *integrate* care. When behavioral health (BH) conditions are detected early and treated appropriately, those individuals experience a greater quality of life, better self-care, improved adherence to medical and mental health treatments, and better overall health outcomes.\(^{13}\)

The implementation of regular, validated screening tools along with brief intervention techniques serve as strategies for early detection of SMI and SUDs, resulting in reduced alcohol misuse and earlier intervention and treatment opportunities. When preventive efforts are combined with coordinated care efforts (e.g. psych-consultation, team-care approach, peer providers, enhanced linkages to community and BH settings), the result is a significant improvement in health outcomes. One example of such success is the IMPACT model, which led to two times better clinical outcomes than general care.\(^{14}\) Programs such as the IMPACT model not only improve care at the individual and population levels, but lead to lower overall health care costs.\(^{15}\)

**Goals/Objectives**

To improve physical and behavioral health outcomes, care delivery efficiency and patient experience by establishing or expanding fully integrated care, culturally and linguistically appropriate teams—with expertise in primary care, substance use disorder conditions and mental health conditions delivering coordinated comprehensive care for the whole patient. To integrate mental health and substance abuse with primary care and ensure coordination of care for all services in order to: 1) identify behavioral health diagnoses early, allowing rapid treatment; 2) ensure treatments for medical and behavioral health conditions are compatible and do not cause adverse effects; 3) improve medical and behavioral health outcomes for those patients with chronic medical disorders, and for those with co-occurring physical and behavioral health conditions.

Specific objectives include:

- Increase use of screening tools (e.g. PHQ-9, GAD-7, AUDIT, DAST)
- Improve patient adherence to their treatment regimen
- Improve health indicators for patients with both physical and behavioral chronic conditions

---


\(^{13}\) SAMHSA-HRSA Center for Integrated health Solutions. http://www.integration.samhsa.gov/


\(^{15}\) Jurgen Unützer, Jeffrey Lieberman. Collaborative Care: An Integral Part of Psychiatry’s Future. Psychiatry Online, Psychiatric News Article, November 12, 2013.
<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.1 Integration of Behavioral Health and Primary Care</td>
</tr>
<tr>
<td></td>
<td>• Increase access to mental health and substance use disorder services</td>
</tr>
<tr>
<td></td>
<td>• Reduce preventable acute care utilization</td>
</tr>
<tr>
<td></td>
<td>• Reduce ED visits for patients with behavioral health conditions</td>
</tr>
<tr>
<td></td>
<td>• Improve communication between PCP and behavioral health providers</td>
</tr>
<tr>
<td></td>
<td>• Reduce admissions for patients with behavioral health problems through earlier recognition and intervention</td>
</tr>
<tr>
<td></td>
<td>• Reduce admissions for physical problems by better managing co-morbid behavioral health conditions</td>
</tr>
<tr>
<td></td>
<td>• Improve patient experience</td>
</tr>
<tr>
<td></td>
<td>• Reduce disparities in health and health care</td>
</tr>
<tr>
<td>Core Components</td>
<td>Systems undertaking this project may complete the following components:</td>
</tr>
<tr>
<td></td>
<td>1. Implement a behavioral health integration assessment tool (baseline and annual progress measurement)(^{16,17})</td>
</tr>
<tr>
<td></td>
<td>2. Implement a physical-behavioral health integration program that utilizes a nationally-recognized model (e.g., the Four Quadrant Model for Clinical Integration, the Collaborative Care Model, or other IBH resources from SAMHSA).</td>
</tr>
<tr>
<td></td>
<td>3. Integrate appropriate screening tools and decision support into the emergency department to ensure timely recognition of patients with mental health and substance use disorder problems. Enhanced access to primary care and/or to behavioral health specialists will be integrated into discharge planning for these patients. Use of 24-7 care navigators (e.g., Community Physician Liaison Program) may be used to support linkages to PCPs, MH and SUD specialists and behavioral health and other community services through the discharge process</td>
</tr>
<tr>
<td></td>
<td>4. Physical-behavioral health integration may be an implementation of a new program or an expansion of an existing program, from pilot sites to hospital and health system primary care sites or from single populations to multiple populations, (e.g., obesity, diabetes, maternal, infant, and child care, end-of-life care, chronic pain management).</td>
</tr>
<tr>
<td></td>
<td>5. PCHM and behavioral health providers will:</td>
</tr>
<tr>
<td></td>
<td>a. Collaborate on evidence based standards of care including medication management and care engagement process.</td>
</tr>
<tr>
<td></td>
<td>b. Implement case conferences/consults on patients with complex needs</td>
</tr>
<tr>
<td></td>
<td>6. Ensure coordination and access to chronic disease (physical or behavioral) management, including self-management support to patients and their families.</td>
</tr>
<tr>
<td></td>
<td>7. Ensure systems are in place to support patient linkage to appropriate specialty physical, mental and SUD services. Preventive care screenings including behavioral health</td>
</tr>
</tbody>
</table>

\(^{16}\) e.g., AIMS Center Behavioral Integration Checklist, McHAF Site Self-Assessment

\(^{17}\) Level of Integration Measure (LIM): http://integrationacademy.ahrq.gov/measures/C6%20Level%20of%20Integration%20Measure Purpose: To rate the degree to which behavioral health providers or behavioral health care is integrated into primary care settings from the perspective of staff and/or providers. Developer: Antioch University
### Project Domain
- **Domain 1:** Outpatient Delivery System Transformation and Prevention

### Project Title
- 1.1 Integration of Behavioral Health and Primary Care

Screenings (e.g., PHQ-2, PHQ-9, SBIRT) will be implemented for all patients to identify unmet needs. When screenings are positive, providers will take immediate steps, including provision of brief interventions (e.g., MI techniques) to ensure access for further evaluation and treatment when necessary. Preferably, this should include a warm transfer to the appropriate provider if the screening provider is unable to provide the service.

8. Provide cross-systems training to ensure effective engagement with patients with MH/SUD conditions. Ensure that a sufficient number of providers are trained in SBIRT and/or in other new tools used by providers to ensure effectiveness of treatment.

9. Increase access to Medication Assisted Treatment (MAT) for patients with alcohol and opioid addiction to assist in stabilizing their lives, reducing urges or cravings to use, and encourage greater compliance with treatment for co-morbid medical and mental health conditions. For alcohol use disorders these medications include naltrexone, acamprosate, and disulfiram. For opioid addiction, medication assisted treatment includes maintenance treatment with methadone and buprenorphine.

10. Ensure the development of a single Treatment Plan that includes the patient’s behavioral health issues, medical issues, substance abuse, social and cultural and linguistic needs. This includes incorporating traditional medical interventions, as well as non-traditional interventions such as gym memberships, nutrition monitoring, healthy lifestyle coaching, or access to culturally and linguistically appropriate peer-led wellness and symptoms management groups.

11. Ensure a culturally and linguistically appropriate treatment plan by assigning peer providers or other frontline workers to the care team to assist with care navigation, treatment plan development and adherence.

12. Ensure that the Treatment Plan:
   a. Is maintained in a single shared EHR/clinical record that is accessible across the treatment team to ensure coordination of care planning.
   b. Outcomes are evaluated and monitored for quality and safety for each patient.

13. Implement technology-enabled data systems to support pre-visit planning, point-of-care delivery, care plan development, population/panel management activities, coordination and patient engagement. Develop programs to implement telehealth, eReferral/eConsult to enhance access to behavioral health services.

14. Demonstrate engagement of patients in the design and implementation of the project

15. Increase team engagement by:
   a. Implementing a model for team-based care in which staff performs to the best of their abilities and credentials
   b. Providing ongoing staff training on care model.

16. Ensure integration is efficient and providing value to patients by implementing a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Drug Misuse (SBIRT)</td>
<td>N/A</td>
<td>Oregon CCO</td>
</tr>
</tbody>
</table>

---

California Medi-Cal 2020 Demonstration
Approved December 30, 2015 through December 31, 2020
Amended March 2, 2016
### Measure name

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Care coordinator assignment</td>
<td>N/A</td>
<td>*University of Washington/</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coordinated Care Initiative</td>
</tr>
<tr>
<td>Comprehensive Diabetes Care: HbA1c Poor Control</td>
<td>0059</td>
<td>NCQA</td>
</tr>
<tr>
<td>(&gt;9.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression Remission at 12 Months CMS159v4</td>
<td>0710</td>
<td>MN Community Measurement</td>
</tr>
<tr>
<td>Screening for Clinical Depression and follow-up</td>
<td>0418</td>
<td>CMS</td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling</td>
<td>0028</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>

### Project 1.2 Ambulatory Care Redesign: Primary Care

**Required Project for DPHs**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.2 Ambulatory Care Redesign: Primary Care</td>
</tr>
</tbody>
</table>

**Rationale**

Under the Affordable Care Act primary care providers are seeing an unprecedented increase in the demand for services, with 2.3 million new Californians receiving coverage during the first year of implementation. Demand will continue to grow over the next five years, yet the supply of primary care providers remains relatively static, with fewer than 20% of medical school students choosing a career in primary care. By 2020, the demand for care is expected to outpace the supply of primary care providers.

In order to meet the growing demand for services, participating PRIME entities must become more efficient, better-coordinated systems of care. Patient-centered medical homes (PCMH) show promise for improving the efficiency and effectiveness of primary care by leveraging the skills of non-physicians and sharing responsibilities among a care team. Nurse practitioners and physicians assistants, for example, are entering the field at a greater rate than primary care providers and can offer increased capacity and quality to the primary care team. By sharing responsibilities among members of the care team, the medical home can relieve the burden on primary care providers and allow all staff to maximize their skills, resulting in enhanced collaborative care with patients.

In addition to redesigning care to support the medical home model, participating PRIME entities can leverage new technologies to expand primary care access and improve quality of care. Reaching patients through alternate modes, such as patient portals, is both convenient for patients and shown to improve clinical quality measures. Disease registries and electronic medical records are powerful tools for improving care coordination and quality improvement.

---


reminders can increase screening rates for chronic illness and keep vulnerable patients from “falling through the cracks.” Under the PCMH model, the care team uses data to drive decision-making, becoming more efficient and effective providers of care.

This delivery system transformation will require re-thinking traditional provider roles and engaging all levels of staff to work together in coordinated teams. It will require processes for improved provider-provider and provider-patient communication, both in-person and remote. Transformation will also require building the data capacity to support alternate modes of care delivery, build robust disease registries, and make data available to care teams in real time, so they can work collaboratively with patients to make the best decisions for optimum health outcomes.

Furthermore, in addition to transforming care for all patients, participating PRIME entities must reduce disparities in health and healthcare between patient populations. The PRIME Primary Care Redesign project will require participating PRIME entities deliver targeted interventions that address the specific needs of underrepresented populations and communities of color, and target resources to improve health equity. The approach to incorporate disparities reduction into quality improvement initiatives aligns with direction from the Institute of Medicine, which includes equity as a cross-cutting dimension of all quality care.

**Goals/Objectives**

Patients will experience timely access to high quality, efficient, and equitable primary care, designed to work collaboratively with patients and other care providers in achieving and maintaining optimum patient health, and avoiding unplanned interventions.

Specific objectives include:

- Increase the number of primary care practices undergoing Patient Centered Medical Home transformation, most notably implementing team based care and better utilization of front line workers
- Increase provision of recommended preventive health services
- Improve health indicators for patients with chronic condition(s) (including mental health and substance use disorder conditions)
- Increase patient access to care
- Decrease preventable acute care utilization
- Improve patient experience of care
- Increase staff engagement
- Improve the completeness, accuracy, and specificity of race, ethnicity, and language (REAL), and sexual orientation and gender identity (SO/GI) data
- Reduce disparities in health and health care

**Core Components**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.2 Ambulatory Care Redesign: Primary Care</td>
</tr>
</tbody>
</table>

Systems undertaking this project may complete the following components:

1. Gap analysis of practice sites within the DPH/DMPH system.
2. Primary Care practices will demonstrate advancement of their PCMH transformation through the use of a nationally recognized PCMH methodology\textsuperscript{23}
3. Hiring and training of frontline workforce (e.g., medical assistants, community health workers, promotoras, health navigators or other non-licensed members of the care team) to be responsible for coordination of non-clinical services and elements of the care plan.
4. Implement technology-enabled data systems to support pre-visit planning, point of care delivery, population/panel management activities, care coordination, patient engagement, and operational and strategic decisions including a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.
   a. Implementation of Electronic Health Record (EHR) technology that meets meaningful use standards (MU)
5. Ongoing identification of all patients for population management (including assigned managed care lives):
   a. Manage panel size, assignments, and continuity to internal targets;
   b. Develop interventions for targeted patients by condition, risk, and self-management status.
   c. Perform preventive care services including mental health and substance misuse screenings and brief interventions (e.g., PHQ-9, SBIRT).
6. Enable prompt access to care by:
   a. Implementing open or advanced access scheduling
   b. Creating alternatives to face-to-face provider/patient visits
   c. Assigning frontline workers to assist with care navigation and non-clinical elements of the care plan.
7. Coordinate care across settings
   a. Identification of care coordinators at each primary care site who are responsible for coordinating care within the PCMH as well as with other facilities (e.g., other care coordinators or PCMH/DPH/DMPH high risk care managers)
      i. Establish onsite Care/Case managers to work with high risk patients and their care teams, or develop processes for local care coordinators to work with a central complex care management program for these patients
   b. Implement processes for timely bi-directional communication and referral to specialty care, (including mental health and substance use disorder services), acute care, social services and community based services
8. Demonstrate evidence-based preventive and chronic disease management

### Project Domain

**Domain 1: Outpatient Delivery System Transformation and Prevention**

### Project Title

1.2 Ambulatory Care Redesign: Primary Care

9. Improve staff engagement by:
   a. Implementing a model for team-based care in which staff performs to the best of their abilities and credentials.
   b. Providing ongoing staff training on the team-based care model to ensure effective and efficient provision of services (e.g., group visits, medication reconciliation, motivational interviewing, cognitive behavioral therapy and Medication-Assistance Treatment (MAT)).

10. Engage patients using care plans, and self-management education, and through involvement in the design and implementation of this project.

11. Improve the accuracy and completeness of race, ethnicity, and language (REAL), and sexual orientation and gender identity (SO/GI) data, and use that data to identify and reduce disparities in one or more Primary Care Redesign project metrics by:
   a. Adding granular REAL and SO/GI data to demographic data collection processes and training front-line/registration staff to gather complete and accurate REAL/SO/GI data
   b. Developing capacity to track and report REAL/SO/GI data, and data field completeness
   c. Implementing and/or refining processes for ongoing validation of REAL/SO/GI data
   d. Developing capacity to stratify performance metrics by REAL/SO/GI data and use stratified performance data to identify disparities for targeted interventions
   e. Developing capacity to plan and implement disparity reduction interventions with input from patients and community stakeholders
   f. Developing dashboards to share stratified performance measures with front-line staff, providers, and senior leadership.

12. To address quality and safety of patient care, implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Drug Misuse (SBIRT)</td>
<td>N/A</td>
<td>Oregon CCO</td>
</tr>
<tr>
<td>CG-CAHPS: Provider Rating</td>
<td>0005</td>
<td>AHRQ</td>
</tr>
<tr>
<td>Colorectal Cancer Screening</td>
<td>0034</td>
<td>NCQA</td>
</tr>
<tr>
<td>Comprehensive Diabetes Care: HbA1c Poor Control (&gt;9.0%)</td>
<td>0059</td>
<td>NCQA</td>
</tr>
<tr>
<td>Controlling Blood Pressure</td>
<td>0018</td>
<td>NCQA</td>
</tr>
<tr>
<td>Documented REAL and/or SO/GI disparity reduction</td>
<td>N/A</td>
<td>*DHCS</td>
</tr>
<tr>
<td>Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</td>
<td>0068</td>
<td>NCQA</td>
</tr>
<tr>
<td>Prevention Quality Overall Composite #90</td>
<td>N/A</td>
<td>AHRQ</td>
</tr>
</tbody>
</table>
3. **Project 1.3 Ambulatory Care Redesign: Specialty Care**

**Required Project for DPHs**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.3 Ambulatory Care Redesign: Specialty Care</td>
</tr>
</tbody>
</table>

**Rationale**

While a strong primary care service is an essential component of an effective health system, efficient linkage to specialty care, including mental health and substance use services, is also critical. The rapid increase in patients eligible for health care and other drivers necessitate system redesign that enables patients to access specialists in more efficient ways since the demand for such care is increasing while the supply is static. Increased “supply” is achievable through expansion of the specialty care team, improved efficiency in the provision of care (both in person and virtual), improved coordination and collaboration with referring providers, and enhanced engagement of patients and families.

Timely access to specialty care continues to be a challenge for patients of DPHs, the largest provider of specialty care in California’s safety net, and DMPHs. Delays can lead to adverse medical outcomes, increased ED utilization, and higher health care costs. Many patients experience fragmented care, with multiple care plans and little communication between providers. To improve timely access to specialty care, DPHs/DMPHs are redesigning processes that link patients and providers to specialists, particularly by leveraging new technology for remote communication.

Participating PRIME entities transformation into patient-centered medical homes involves improving the

---

24 As per the [2015 Final Rule on Certified EHR Technology](#), record each one of a patient’s races and ethnicities in accordance with, at a minimum, the “Race & Ethnicity – CDC” code system in the PHIN Vocabulary Access and Distribution System (VADS), Release 3.3.918 and use the [Internet Engineering Task Force (IETF) Request for Comments (RFC) 5646](#) standard for preferred language.

25 Refer to [2015 Final Rule on Certified EHR Technology](#), pages 56-57 for recommended SO/GI “best practice” questions, and pages 495-497 for SO/GI SNOMED and HL7 codes sets.


collaborative partnership between specialists and the primary care team. The proposed PRIME project provides a structure and goals to guide this transformation. Primary care providers and specialists develop a co-management plan, which clearly defines their roles and responsibilities in caring for a patient, and outlines the protocol for care coordination. Increasingly, this coordination involves the use of telehealth technology, such as electronic referrals and consults, and real time patient/provider virtual visits. Telehealth is a promising strategy for improving coordination between all parties. Electronic referrals and consultations allow bi-directional primary care-specialist communications, coordination and co-management to minimize the number of visits a patient will need and optimize required visits thus reducing historically long wait-times for new and follow-up appointments. In addition to increasing coordination, technology can also improve the quality of care.

Redesigning specialty care will involve more than new technology — it will require a shift in the relationship between primary care providers (PCPs) and specialists. Under the patient-centered medical home model, PCPs and specialists work together as part of a single care team, organized around the needs of the patient. The project involves enhancing the engagement of patients and families, expanding the roles of non-providers on the specialty care team, leveraging technology to increase timely access to specialty care expertise, integrating specialists into the system care team through improved communication and coordination between providers, and implementing data systems and workflows to support more efficient care delivery.

Goals/Objectives

Patients will experience timely access to high quality, effective specialty care, including care for mental health and substance use services, designed to work collaboratively with patients and their PCPs, in achieving and maintaining optimum patient health, and avoiding unplanned interventions. Redesign of specialty care system processes will include improvements to be patient centric, expand the use of non-physician care team members, implement alternatives to face-to-face, patient-provider encounters, including the use of telehealth solutions, and engage in population health management strategies.

Specific objectives include:

- Partner with Patient Centered Medical Home (PCMH) to improve health outcomes in acute and chronic disease
  - Increase patient and provider access to specialty expertise— delivered in the most effective means to meet the need.
  - Provide resources to PCPs to increase their capacity to care for complex patients
- Decrease avoidable acute care utilization
- Improve Patient Experience
- Increase specialty care staff engagement
- Right size number of specialists for target population
- Reduce disparities in health and health care

Core Components

<table>
<thead>
<tr>
<th><strong>Project Domain</strong></th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Project Title</strong></td>
<td>1.3 Ambulatory Care Redesign: Specialty Care</td>
</tr>
</tbody>
</table>

Participating PRIME entities undertaking this project may complete the following components:

1. Develop a specialty care program that is broadly applied to the entire population of service.
2. Conduct a gap analysis to assess need for specialty care including mental health and SUD services (analysis to include factors impacting ability to access specialty care), and the current and ideal state capacity to meet that need. Benchmark to other CA Public Health Care systems.
   a. For ideal state analysis, include potential impact of increased primary care capacity to manage higher acuity conditions either independently, or in collaboration with, specialty care, so as to reduce the need for in-person specialty care encounters. (e.g., insulin titration, IBS management, joint injections, cognitive behavioral therapy (CBT) or Medication Assisted Treatment (MAT)).
3. Engage primary care providers and local public health departments in development and implementation of specialty care model
   a. Implement processes for primary care: specialty care co-management of patient care
   b. Establish processes to enable timely follow up for specialty expertise requests
   c. Develop closed loop processes to ensure all requests are addressed and if in person visits are performed, that the outcome is communicated back to the PCP.
4. Clinical teams engage in team- and evidence-based care
5. Increase staff engagement by:
   a. Implementing a model for team-based care in which staff performs to the best of their abilities and credentials.
   b. Providing ongoing staff training on care model
6. Develop and implement standardized workflows for diversified care delivery strategies (e.g. shared medical visits, ancillary led services, population management, telemedicine services) to expand access and improve cost efficiency
7. Adopt and follow treatment protocols mutually agreed upon across the delivery system
8. Implement technology-enabled data systems to support pre-visit planning, point of care delivery, population management activities and care coordination/transitions of care. Timely, relevant and actionable data is used to support patient engagement, PCP collaboration, and drive clinical, operational and strategic decisions including continuous QI activities.
   a. Implement EHR technology that meets meaningful use standards (MU)
9. Patients have care plans and are engaged in their care. Patients with chronic disease (including MH/SUD conditions) managed by specialty care have documented patient-driven, self-management goals reviewed at each visit
10. Improve medication adherence
11. Implement population management strategies for patients in need of preventive services, with chronic conditions, or with recurring long term surveillance needs
12. Implement or expand use of telehealth based on DPH/DMPH capacity to address patient and PCP barriers to accessing specialty expertise. Implement a telehealth platform with communication modalities that connect between specialty care and primary care (e.g., eConsult/eReferral)
13. Demonstrate engagement of patients in the design and implementation of the project
14. Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.
15. Test use of novel performance metrics for redesigned specialty care models

**Required Project Metrics**
<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Closing the referral loop: receipt of specialist report (CMS50v3)</td>
<td>N/A</td>
<td>CMS</td>
</tr>
<tr>
<td>DHCS All-Cause Readmissions</td>
<td>N/A</td>
<td>DHCS</td>
</tr>
<tr>
<td>Influenza Immunization</td>
<td>0041</td>
<td>NCQA</td>
</tr>
<tr>
<td>Post procedure ED visits</td>
<td>N/A</td>
<td>*San Francisco Health Network (SFHN)</td>
</tr>
<tr>
<td>Referral Reply Turnaround Rate</td>
<td>N/A</td>
<td>*Los Angeles County Department of Health Services (LAC DHS), SFHN</td>
</tr>
<tr>
<td>Specialty Care Touches: Specialty expertise requests managed via non-face to face specialty encounters</td>
<td>N/A</td>
<td>*LAC DHS, UC Davis</td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling</td>
<td>0028</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>
4. **Project 1.4 Patient Safety in the Ambulatory Setting**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.4 Patient Safety in the Ambulatory Setting</td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td>Despite the fact that the vast majority of health care takes place in the ambulatory care setting, efforts to improve safety have mostly focused on the inpatient setting. The ambulatory environment is prone to problems and errors that include missed/delayed diagnoses, delay of proper treatment or preventive services, medication errors/adverse drug events, and ineffective communication and information flow. However, compared with the hospital environment, there has been considerably less research, metric development, and interventions implemented to address these identified patient safety concerns. Because it is self-evident that outpatient patient safety issues can lead to preventable morbidity and mortality, improving quality in this domain remains a critical target even though some approaches will need to be developmental and innovative in the absence of consensus national measures and guidelines. Participating PRIME entities will focus their improvement efforts on the most common tests ordered in the outpatient setting for which prompt follow-up is typically required of clinically significant and either critical or sub-critical abnormal results. The focus on annual monitoring of patients on persistent medications and abnormal but subcritical results is impactful because no standard or workflow governs management of such results, in contrast to critical-range abnormal results, and these tests are a known vulnerability.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Goals/Objectives</strong></th>
<th>To implement standardized monitoring, alert notification and response workflows to ensure the health and safety of individuals for whom diagnostic testing has been performed and for those on medications for chronic conditions. Specific objectives include:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Ensure that abnormal test results are conveyed to the ordering clinician and that appropriate follow-up is implemented.</td>
</tr>
<tr>
<td></td>
<td>• Ensure annual monitoring being done for patients on persistent medications</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Core Components</strong></th>
<th>Participating PRIME entities undertaking this project may complete the following components:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Perform a baseline studies to examine the current workflows for abnormal results follow-up and monitoring of individuals on persistent medications.</td>
</tr>
<tr>
<td>2.</td>
<td>Implement a data-driven system for rapid cycle improvement and performance feedback based on the baseline study that effectively addresses all identified gaps in care and which targets clinically significant improvement in care. The improvement and performance feedback system should include patients, front line staff from testing disciplines (such as, but not limited to, radiology and laboratory medicine) and ordering disciplines (such as primary care) and senior leadership.</td>
</tr>
</tbody>
</table>

---

Project Domain | Domain 1: Outpatient Delivery System Transformation and Prevention
---|---
Project Title | 1.4 Patient Safety in the Ambulatory Setting

3. Develop a standardized workflow so that:
   - Documentation in the medical record that the targeted test results were reviewed by the ordering clinician;
     - Use the American College of Radiology’s Actionable Findings Workgroup[^33] for guidance on mammography results notification.
   - Evidence that every abnormal result had appropriate and timely follow-up; and
   - Documentation that all related treatment and other appropriate services were provided in a timely fashion as well as clinical outcomes documented.

4. In support of the standard protocols referenced in #2:
   - Create and disseminate guidelines for critical abnormal result levels
   - Creation of protocol for provider notification, then patient notification
   - Script notification to assure patient returns for follow up
   - Create follow-up protocols for difficult to reach patients

5. Implement technology-enabled data systems to support the improvement and performance feedback system as well as engage patients and support care teams with patient identification, pre-visit planning, point of care delivery, and population/panel management activities.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal Results Follow-Up</td>
<td>N/A</td>
<td>*Alameda Health System (AHS)</td>
</tr>
<tr>
<td>Annual Monitoring for Patients on Persistent Medications</td>
<td>2371</td>
<td>NCQA</td>
</tr>
<tr>
<td>INR Monitoring for Individuals on Warfarin</td>
<td>0555</td>
<td>CMS</td>
</tr>
</tbody>
</table>

5. **Project 1.5 Million Hearts Initiative**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.5 Million Hearts® Initiative</td>
</tr>
<tr>
<td>Rationale</td>
<td>According to the California Department of Public Health, heart disease and stroke were the first and third leading causes of death among Californians, respectively, accounting for 24.6 percent and 5.8 percent of deaths in 2010. Risk factors for heart disease, such as tobacco use and hypertension, need to be reduced in order to improve cardiovascular health. The California Health Interview Survey and Behavioral Risk Factor Surveillance System indicate that 20 percent of Medi-Cal members use tobacco, compared to the State average of 12 percent. In addition, 37 percent of adult Medi-Cal members have been diagnosed with hypertension at some point in their lives.</td>
</tr>
</tbody>
</table>

In 2011, the US Department of Health and Human Services launched the Million Hearts® initiative to prevent 1 million heart attacks and strokes by 2017 through public and private commitments to:

- Improve care for people who need treatment by encouraging health systems and health professionals to focus on the “ABCS”—Aspirin when appropriate, Blood pressure control, Cholesterol management, and Smoking cessation—which address the major risk factors for cardiovascular disease and can help to prevent heart attacks and stroke.
- Empower Americans to make healthy choices, such as preventing tobacco use and reducing sodium and trans fat consumption. These efforts can reduce the number of people who need medical treatment, including blood pressure or cholesterol medications, to prevent heart attacks and stroke.

DHCS is participating in the Centers for Medicare and Medicaid Services’ Prevention Learning Network to advance the Million Hearts® initiative in California. As a result, Medi-Cal Managed Care Plans are participating in QI learning collaboratives to improve hypertension control and reduce tobacco use prevalence. In addition, the Department is collaborating with the California Department of Public Health and Right Care Initiative to advance Million Hearts®. The Department also supports the efforts of the $10 million, 5-year Medi-Cal Incentives to Quit Smoking Project to significantly reduce tobacco use. These activities and partnerships make the designated public hospitals well positioned to meet the clinical goals of Million Hearts®.

<table>
<thead>
<tr>
<th>Goals/Objectives (Project-specific prevention goals and expected project outcomes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implement collaboratively identified and standardized, evidence-based and population resource stewardship approaches to the use of targeted preventive services across multiple participating PRIME entities. Collaborate among participating PRIME entities on approaches to meet clinical targets that</td>
</tr>
</tbody>
</table>

---

37 AskCHIS, California Health Interview Survey, 2011-2012.
Project Domain | Domain 1: Outpatient Delivery System Transformation and Prevention
---|---
Project Title | 1.5 Million Hearts® Initiative

support the Million Hearts® initiative, starting with tobacco cessation, hypertension control, and appropriate low-dose aspirin use.

Specific objectives include:

- Identify cost effective, evidence-based approaches to:
  - Support the Million Hearts® initiative clinical targets, starting with tobacco cessation, hypertension control, and appropriate aspirin use
- Reduce disparities in receipt of targeted prevention services
- Reduce variation and improve performance on Million Hearts® initiative goals across multiple DPHs/DMPHs

Core Components

Systems undertaking these projects may complete the following components:

- Collect or use preexisting baseline data on receipt and use of targeted preventive services, including any associated disparities related to race, ethnicity or language need. See figures 1 and 2 for related data among the Medi-Cal population.
- Implement processes to provide recommended clinical preventive services in line with national standards, including but not limited to the US Preventive Services Task Force (USPSTF) A and B Recommendations.
- Improve access to quality care and decrease disparities in the delivery of preventive services.
- Employ local, state and national resources, and methodologies for improving receipt of targeted preventive services, reducing associated disparities, and improving population health.
- Adopt and use certified electronic health record systems, including clinical decision supports and registry functionality to support provision of targeted preventive services. Use panel/population management approaches (e.g., in-reach, outreach) to reduce gaps in receipt of care.
- Based on patient need, identify community resources for patients to receive or enhance targeted services and create linkages with and connect/refer patients to community preventive resources, including those that address the social determinants of health, as appropriate.
- Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership
  - Provide feedback to care teams around preventive service benchmarks and incentivize QI efforts.
- Encourage, foster, empower, and demonstrate patient engagement in the design and implementation of programs.

Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlling Blood Pressure</td>
<td>0018</td>
<td>NCQA</td>
</tr>
<tr>
<td>Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</td>
<td>0068</td>
<td>NCQA</td>
</tr>
<tr>
<td>PQRS # 317 Preventative Care and Screening: Screening for High Blood Pressure and Follow-Up Documented</td>
<td>N/A</td>
<td>CMS</td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling</td>
<td>0028</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>
6. **Project 1.6 Cancer Screening and Follow-up**

<table>
<thead>
<tr>
<th><strong>Project Domain</strong></th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Project Title</strong></td>
<td>1.6 Cancer Screening and Follow-up</td>
</tr>
</tbody>
</table>
| **Rationale** (Evidence base and reasoning for project idea) | Cancer is the second leading cause of mortality in California, accounting for nearly 1 out of every 4 deaths. The risk of developing cancer varies considerably by race/ethnicity. For example, African American men have the highest overall cancer rate, followed by non-Hispanic white men. Among women, non-Hispanic white women are most likely to be diagnosed with cancer, but African American women are more likely to die of the disease. The reasons for racial/ethnic differences in cancer risk and developing cancer is likely the result of a complex combination of dietary, lifestyle, environmental, occupational, and genetic factors. Higher mortality rates among some populations are due in part to poverty, which may increase the risk of developing certain cancers and limit access to and utilization of preventive measures and screening. |}

Regular screening tests offer the ability for secondary prevention by detecting cancer early, before symptoms appear. Screening tests that allow the early detection and removal of precancerous growth are known to reduce mortality of cancers of the cervix, colon, and rectum. Early diagnosis can also save lives by identifying cancers when they require less expensive treatment and have better outcomes. Five-year relative survival rates for common cancers, such as those of the breast, colon and rectum, and cervix, are 93 percent to 100 percent if they are discovered before having spread beyond the organ where the cancer began.

| **Goals/Objectives** | Implement collaboratively-identified, standardized, evidence-based and population resource stewardship approaches to the use of targeted preventive services across multiple participating PRIME entities. Develop consensus across participating PRIME entities on approaches to a select group of cancer screening and follow-up services with high clinical impact, and variation in resource utilization and performance. Increase receipt of these services by participating PRIME entity patients while reducing associated participating PRIME entity variation in approach, performance and disparities of receipt of services across the population. Specific objectives include:  
- Identify cost-effective standard approaches to Breast, Cervical and Colorectal Cancer screening and completion of follow-up on abnormal screening tests  
- Increase rates of screening and completion of follow-up across targeted prevention services  
- Reduce disparities in receipt of targeted prevention services  
- Reduce variation in performance of targeted prevention services across multiple participating PRIME entities |

40 *Ibid.* p. 3 |
### Project Domain
Domain 1: Outpatient Delivery System Transformation and Prevention

### Project Title
1.6 Cancer Screening and Follow-up

Systems undertaking this project may complete the following components:

- Develop a multi-disciplinary cross-participating PRIME entity task force to identify principle-based expected practices for screening and follow-up for the targeted services including, but not limited to:
  - Standard approach to screening and follow-up within each DPH/DMPH
  - Screening:
    - Enterprise-wide standard approach to screening (e.g., ages, frequency, diagnostic tool)
  - Follow-up for abnormal screening exams:
    - Clinical risk-stratified screening process (e.g., family history, red flags)
    - Timeliness (specific time benchmark for time from abnormal screening exam to diagnostic exam)

- Demonstrate patient engagement in the design and implementation of programs.
- Collect or use preexisting baseline data on receipt and use of targeted preventive services, including any associated disparities related to race, ethnicity or language need.
- Implement processes to provide recommended clinical preventive services in line with national standards, including but not limited to USPSTF A and B Recommendations.
- Improve access to quality care and decrease disparities in the delivery of preventive services.
- Employ local, state and national resources, and methodologies for improving receipt of targeted preventive services, reducing associated disparities, and improving population health.
- Adopt and use certified electronic health record systems, including clinical decision supports and registry functionality to support provision of targeted preventive services. Use panel/population management approaches (e.g., in-reach, outreach) to reduce gaps in receipt of care.
- Based on patient need, identify community resources for patients to receive or enhance targeted services and create linkages with and connect/refer patients to community preventive resources, including those that address the social determinants of health, as appropriate.
- Implement a system for continual performance management and rapid cycle improvement that includes feedback from patients, community partners, front line staff, and senior leadership.

#### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIRADS to Biopsy</td>
<td>N/A</td>
<td>*Los Angeles County Department of Health Care Services, San Francisco Health Network</td>
</tr>
<tr>
<td>Breast Cancer Screening</td>
<td>2372</td>
<td>NCQA</td>
</tr>
<tr>
<td>Cervical Cancer Screening</td>
<td>0032</td>
<td>NCQA</td>
</tr>
<tr>
<td>Colorectal Cancer Screening</td>
<td>0034</td>
<td>NCQA</td>
</tr>
<tr>
<td>Receipt of appropriate follow-up for abnormal CRC screening</td>
<td>N/A</td>
<td>*San Francisco Health Network</td>
</tr>
</tbody>
</table>

---

7. **Project 1.7 Obesity Prevention and Healthier Foods Initiative**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 1: Outpatient Delivery System Transformation and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>1.7 Obesity Prevention and Healthier Foods Initiative</td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td>Approximate two-thirds of adults and one-third of children and adolescents are overweight or obese, and the prevalence is higher among low-income populations. Evidence suggests that as weight increases to reach the levels referred to as “overweight” and “obese,” the risk of several serious conditions, such as heart disease and hypertension, also increases. According to the US Preventive Services Task Force, all adults and children, ages 6 and older, should be screened for obesity and referred to behavioral interventions, as appropriate. In the broader clinical environment, the Centers for Disease Control and Prevention and Harvard School of Public Health recommend increasing the availability and affordability of healthful food and beverages in hospitals and other public venues as one key strategy to prevent obesity in the United States. Hundreds of hospitals have successfully implemented the Partnership for a Healthier America’s Hospital Healthier Foods Initiative guidelines, including well-known teaching hospitals, such as the Cleveland Clinic Foundation and the Henry Ford Health System. There is a wide variety of obesity prevention and management efforts occurring throughout the state of California. The California Department of Health Care Services partners with the California Department of Social Services to reduce overweight and obesity among Medi-Cal members. This project serves as a natural complement to obesity prevention and management activities happening throughout California.</td>
</tr>
<tr>
<td><strong>Goals/Objectives</strong></td>
<td>Implement collaboratively identified and standardized, evidence-based and population resource stewardship approaches to the use of targeted preventive services across participating PRIME entities. Collaborate among participating PRIME entities on approaches to meet obesity screening and referral to treatment targets, and the Partnership for a Healthier America’s Hospital Healthier Food Initiative. Specific objectives include:</td>
</tr>
<tr>
<td>- Identify cost-effective, evidence-based approaches to:</td>
<td></td>
</tr>
<tr>
<td>- Implement obesity screening and referral to treatment for pediatric and adult populations</td>
<td></td>
</tr>
<tr>
<td>- Reduce disparities in receipt of targeted prevention services</td>
<td></td>
</tr>
<tr>
<td>- Reduce variation and improve performance on obesity screening and referral to treatment across multiple participating PRIME entities</td>
<td></td>
</tr>
<tr>
<td>- Support the provision of healthful foods in clinical facilities by implementing the Partnership for a Healthier America’s Hospital Healthier Food Initiative</td>
<td></td>
</tr>
<tr>
<td><strong>Core Components</strong></td>
<td>Systems undertaking these projects may complete the following components:</td>
</tr>
</tbody>
</table>

---

### Project Domain
**Domain 1: Outpatient Delivery System Transformation and Prevention**

### Project Title
1.7 Obesity Prevention and Healthier Foods Initiative

- Collect or use preexisting baseline data on receipt and use of targeted preventive services, including any associated disparities related to race, ethnicity or language need.
- Implement processes to provide recommended clinical preventive services in line with national standards, including but not limited to USPSTF A and B Recommendations.
- Improve access to quality care and decrease disparities in the delivery of preventive services.
- Employ local, state and national resources, and methodologies for improving receipt of targeted preventive services, reducing associated disparities, and improving population health.
- Adopt and use certified electronic health record systems, including clinical decision supports and registry functionality to support provision of targeted preventive services. Use panel/population management approaches (e.g., in-reach, outreach) to reduce gaps in receipt of care.
- Based on patient need, identify community resources for patients to receive or enhance targeted services and create linkages with and connect/refer patients to community preventive resources, including those that address the social determinants of health, as appropriate.
- Implement a system for performance management that includes ambitious targets and feedback from patients, community partners, front line staff, and senior leadership, and a system for continual rapid cycle improvement using standard process improvement methodology.
  - Provide feedback to care teams around preventive service benchmarks and incentivize QI efforts.
- Encourage, foster, empower, and demonstrate patient engagement in the design and implementation of programs.
- Prepare for and implement the Partnership for a Healthier America’s Hospital Healthier Food Initiative

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI Screening and Follow-up</td>
<td>0421</td>
<td>CMS</td>
</tr>
<tr>
<td>Partnership for a Healthier America's Hospital Health Food Initiative external food service verification</td>
<td>N/A</td>
<td>DHCS</td>
</tr>
<tr>
<td>Weight Assessment &amp; Counseling for Nutrition and Physical Activity for Children &amp; Adolescents</td>
<td>0024</td>
<td>NCQA</td>
</tr>
</tbody>
</table>
B.  Domain 2: Targeted High-Risk or High-Cost Populations
   Projects 2.1-2.3 Required for DPHs

The projects in this domain focus on specific populations that would benefit most significantly from care integration and coordination: individuals with chronic non-malignant pain and those with advanced. The projects on Improved Perinatal Care, Care Transitions: Integration of Post-Acute Care and Complex Care Management for High-Risk Medical Populations will be required of all participating DPH systems.
1. **Project 2.1 Improvements in Perinatal Care**  
   **Required Project for DPHs**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High Risk Or High Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.1 Improvements in Perinatal Care</td>
</tr>
<tr>
<td>Rationale</td>
<td>(Evidence base and reasoning behind project idea)</td>
</tr>
</tbody>
</table>

**Approximately 500,000 babies are born each year in California**, and ensuring a healthy pregnancy, delivery, and beginning of life are crucial to fostering a healthy population. Unfortunately, rates of maternal mortality and severe maternal morbidity in both the United States and California doubled in the 10 years between 1999 and 2008 in California. Medical procedures during childbirth have markedly increased, including primary and repeat cesareans, labor inductions and early elective deliveries often when they are not medically indicated; practices that result in higher costs and higher rate of complications for both women and babies. Furthermore, there are notable racial differences for key pregnancy outcomes. California data indicate that non-Hispanic black women are more likely to have cesareans, and have 3-4 times higher rates of maternal death and morbidity. Overall, cesarean deliveries in California rose from 22 to 33 percent between 1998 and 2008, and now total more than 165,000 per year. While the statewide cesarean delivery rate was 33 percent in 2012, there was exceptionally large variation among hospitals with some outlier hospitals had rates as high as 80.9 percent. On the other hand, 36 percent of California hospitals were already meeting the national Healthy People 2020 target of 23.9 percent for low-risk first-birth hospitals. This finding indicates that significant reduction is not only possible but already achieved by one-third of our hospitals. Participating PRIME entities also have significant variation among all of these measures suggesting significant opportunities for improvement.

Several multi-disciplinary and multi-stakeholder statewide initiatives are currently in place to address perinatal care quality and safety. These programs have the goal to improve the health of women and children and to ensure these health services are delivered safely, efficiently, and equitably.

These statewide initiatives include:

- The California Maternal Quality Care Collaborative (CMQCC). CMQCC has engaged a wide range of stakeholders across the State to improve health outcomes of mothers and newborns through best practices. The CMQCC’s California Maternal Data Center (CMDC) supports QI activities by generating perinatal performance metrics.
- The Patient Safety First (PSF) initiative funded by Anthem Blue Cross has been working with over 100 California hospitals since 2009 in several patient safety areas, including obstetrics.
- The recent formation of the Hospital Quality Institute (HQI) by the California Hospital

---


48 Main, Elliott et al. Cesarean Deliveries, Outcomes, and Opportunities for Change in California: Toward a Public Agenda for Maternity Care Safety and Quality, 2011

49 Personal Communication with Elliot Main. The California Maternal Data Center (CMDC) slide deck, California Maternal Quality Care Collaborative, July 24, 2013
Association (CHA) is committed to improving maternity care.

The first three of these organizations are working closely together in a unified program to support hospital-based maternity QI to reduce maternal mortality, morbidity and unneeded obstetric procedures. These initiatives are now national in scope, all being part of the National Partnership for Maternal Safety supported by ACOG, AWHONN, AHA, TJC, CMS/CMMI, and many other women’s health organizations.

**Goals/Objectives**

- Support breastfeeding initiation, continuation, and baby-friendly practices.
- Ensure and support best practices to prevent morbidity and mortality associated with obstetrical hemorrhage.
- Decrease statewide cesarean section rate, and decrease variability in cesarean section rates in hospitals throughout California.
- Improve maternal morbidity and mortality statewide.
- Ensure women receive comprehensive, evidenced-based, and timely prenatal and postpartum care.
- Postpartum care should effectively address and support breastfeeding initiation and continuation, contraception, and ensure follow-up and treatment of medical co-morbidities.

**Core Components**

Systems undertaking this project may complete the following components:

- DPHs/DMPHs engagement in best practice learning collaborative to decrease maternal morbidity and mortality related to obstetrical hemorrhage (CMQCC/PSF/HQI combined effort).
- Achieve baby-friendly hospital designation through supporting exclusive breastfeeding prenatally, after delivery, and for 6 months after delivery and using lactation consultants after delivery.
- Encourage best practice and facilitate provider education to improve cesarean section rates, and decrease inequities among cesarean section rates. Participate, as appropriate, in statewide QI initiatives for first-birth low-risk cesarean births.
- Coordinate care for women in the post-partum period with co-morbid conditions including diabetes and hypertension

**Required Project Metrics**

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baby Friendly Hospital designation</td>
<td>N/A</td>
<td>Baby-Friendly USA</td>
</tr>
<tr>
<td>Exclusive Breast Milk Feeding (PC-05)</td>
<td>0480</td>
<td>JNC</td>
</tr>
<tr>
<td>OB Hemorrhage: Massive Transfusion</td>
<td>N/A</td>
<td>CMQCC</td>
</tr>
<tr>
<td>OB Hemorrhage: Total Products Transfused</td>
<td>N/A</td>
<td>CMQCC</td>
</tr>
<tr>
<td>PC-02 Cesarean Section</td>
<td>0471</td>
<td>JNC</td>
</tr>
<tr>
<td>Prenatal and Postpartum Care (PPC)</td>
<td>1517</td>
<td>NCQA</td>
</tr>
<tr>
<td>Severe Maternal Morbidity (SMM) per 100 women with obstetric hemorrhage</td>
<td>N/A</td>
<td>CMQCC</td>
</tr>
<tr>
<td>Unexpected Newborn Complications (UNC)</td>
<td>0716</td>
<td>CMQCC</td>
</tr>
</tbody>
</table>
2. **Project 2.2 Care Transitions: Integration of Post-Acute Care**  
   **Required Project for DPHs**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.2 Care Transitions: Integration of Post-Acute Care</td>
</tr>
</tbody>
</table>

**Rationale**

The transition from inpatient to outpatient settings is a critical point in the care continuum, when providers can link patients to appropriate, ongoing care. All too often, patients are discharged from the hospital without an adequate transition plan and return within the month. According to the Center for Medicare and Medicaid Services, nearly one in five Medicare patients discharged from a hospital are readmitted within 30 days, at a cost of $26 billion each year in Medicare spending.\(^{50}\) While some readmissions are appropriate, many are due to preventable events that could have been avoided.\(^{51}\)

Across the country public hospitals readmissions rates rise above the national average.\(^{52}\) This may be in part because public hospitals serve a large volume of patients with risk factors associated with increased 30-day readmissions, such as co-morbid conditions, low-income status, and mental illness.\(^{53}\) Safety net patients being discharged from inpatient care may not have a stable environment to return to or lack access to reliable care. Given the complex needs of their patients, participating PRIME entities must continue to develop robust care transitions programs that equip patients with a clear discharge plan, empanel them in patient-centered medical homes in collaboration with health plans, and link them to behavioral health and community services. Continued investment in care transitions programs through the PRIME will allow participating PRIME entities to improve coordination between inpatient and outpatient settings and reduce avoidable readmissions across the state.

**Goals/Objectives**

To ensure the coordination and continuity of health care as high-risk patients, with chronic health conditions, behavioral health conditions and/or housing instability, move from the hospital to the ambulatory care setting. To improve patients’ ability to care for themselves, effectively hand off health care responsibility to the appropriate ambulatory care provider, optimize patients’ course of chronic illness and ultimately reduce avoidable acute utilization.

Specific objectives include:

- Improve communication and coordination between inpatient and outpatient care teams
- Increase patients capacity for self-management
- Improve patient experience
- Reduce avoidable acute care utilization

---

\(^{50}\) Center for Medicare and Medicaid Services. Community Based Care Transitions Program.  


<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.2 Care Transitions: Integration of Post-Acute Care</td>
</tr>
<tr>
<td></td>
<td>• Reduce disparities in health and health care</td>
</tr>
</tbody>
</table>

### Core Components

Systems undertaking this project may complete the following components:

1. Develop a care transitions program or expand a care transitions program to additional settings (e.g., emergency department), or to additional populations, using or adapting at least one nationally recognized care transitions program methodology\(^{54}\).

2. Establish or expand on a system to track and report readmission rates, timeliness of discharge summaries, and other transition processes, and investigate system-specific root causes/risk factors for readmission, using quantitative and qualitative information to identify the key causes of readmissions, including physical, behavioral and social factors.

3. Develop and implement a process, including utilization of data and information technology, to reliably identify hospitalized patients at high-risk for readmission.

4. Develop standardized workflows for inpatient discharge care:
   a. Optimize hospital discharge planning and medication management for all hospitalized patients.
   b. Implement structure for obtaining best possible medication history and for assessing medication reconciliation accuracy.
   c. Develop and use standardized process for transitioning patients to sub-acute and long term care facilities.
   d. Provide tiered multi-disciplinary interventions according to level of risk
      i. Involve mental health, substance use, pharmacy and palliative care when possible
      ii. Involve trained, enhanced IHSS workers when possible
      iii. Develop standardized protocols for referral to and coordination with community behavioral health and social services (e.g., visiting nurses, home care services, housing, food, clothing and social support). Identify and train personnel to function as care navigators for carrying out these functions.

5. Inpatient and Outpatient teams will collaboratively develop standardized transition workflows:
   a. Develop mechanisms to support patients in establishing primary care for those without prior primary care affiliation
   b. Develop process for warm hand-off from hospital to outpatient provider, including assignment of responsibility for follow-up of labs or studies still pending at the time of discharge.

6. Develop standardized workflows for post-discharge (outpatient) care:
   a. Deliver timely access to primary and/or specialty care following a hospitalization
   b. Standardize post-hospital visits and include outpatient medication reconciliation.

7. Support patients and family caregivers in becoming more comfortable, competent and confident in self-management skills required after an acute hospitalization by providing:

---

\(^{54}\) E.g., CMS Discharge Planning Hospital Conditions of Participation, AHRQ Hospital Guide to Reducing Medicaid Readmissions, Coleman Care Transitions Intervention-CTI, Project BOOST, STAAR, Project RED
Project Domain | Domain 2: Targeted High-Risk Or High-Cost Populations
---|---
Project Title | 2.2 Care Transitions: Integration of Post-Acute Care

- Engagement of patients in the care planning process
- Pre-discharge patient and caregiver education and coaching
- Written transition care plan for patient and caregiver
- Timely communication and coordination with receiving practitioner
- Community-based support for the patient and caregiver post hospitalization focusing on self-care requirements and follow-up care with primary and specialty care providers.

8. Engage with local health plans to develop transition of care protocols that ensure: coordination of care across physical health, substance use disorder and mental health spectrum will be supported, identification of and follow-up engagement with PCP is established, covered services including DME will be readily available; and a payment strategy for the transition of care services is in place.

9. Demonstrate engagement of patients in the design and implementation of the project.

10. Increase multidisciplinary team engagement by:
   - Implementing a model for team-based care in which staff performs to the best of their abilities and credentials
   - Providing ongoing staff training on care model.

11. Implement a system for continual performance feedback and rapid cycle improvement that uses standard process improvement methodology and that includes patients, front line staff and senior leadership.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHCS All-Cause Readmissions</td>
<td>N/A</td>
<td>DHCS</td>
</tr>
<tr>
<td>H-CAHPS: Care Transition Metrics</td>
<td>0166</td>
<td>AHRQ</td>
</tr>
<tr>
<td>Medication Reconciliation: 30 days</td>
<td>0097</td>
<td>NCQA</td>
</tr>
<tr>
<td>Reconciled Medication List Received by Discharged Patients</td>
<td>0646</td>
<td>AMA-PCPI</td>
</tr>
<tr>
<td>Timely Transmission of Transition Record</td>
<td>0648</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>
3. **Project 2.3 Complex Care Management for High Risk Medical Populations**  
   **Required Project for DPHs**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.3 Complex Care Management for High-Risk Medical Populations</td>
</tr>
</tbody>
</table>

**Rationale**

A disproportionate share of Medicaid spending in the United States is used to provide care for a relatively small number of patients, with 1% of beneficiaries accounting for the top quartile of total Medicaid expenditures. Among high-cost beneficiaries, nearly two-thirds have co-morbid conditions and one third have co-occurring physical and mental health conditions. These patients incur frequent emergency department (ED) visits and hospitalizations that might have been prevented with less expensive preventive and primary care. Increasingly, payers and providers are investing in complex care management programs that target super-utilizers with coordinated outpatient care to keep them healthy and out of the hospital. Complex care management programs address patients’ physical conditions as well as the co-occurring behavioral health and socioeconomic challenges that increase their likelihood of hospitalization. Successful complex care management programs can improve quality of life for complex patients while dramatically reducing costly ED and hospital stays.

A growing body of literature provides evidence for effective strategies in complex care management. Dr. Clemens Hong, a leader in complex care management research, identifies seven strategies that are commonly used in successful programs: adopt a patient-centered, customized approach to care; use qualitative and quantitative methods to identify high-utilizing patients; prioritize care coordination; build trust between patients and primary care providers; form care teams that meet the patient’s needs; and use technology to enhance care management activities. The proposed PRIME project incorporates these evidence-based best practices and provides a structure for participating PRIME entities to target super-utilizers in their systems. Participating PRIME entities will build on existing care management infrastructure to develop intensive, integrated programs for their most vulnerable patients, with the goal of improving lives and reducing excessive spending.

**Goals/Objectives**

To implement, and/or improve upon, a complex care management model for targeted high-risk patient populations, that facilitates the appropriate coordinated delivery of health care services, is better able to meet the patient’s needs and preferences and results in improvement of the patients’ health outcomes.

---


Project Domain | Domain 2: Targeted High-Risk Or High-Cost Populations
---|---
Project Title | 2.3 Complex Care Management for High-Risk Medical Populations

Specific objectives include:
- Improve patients’ functional status
- Increase patients’ capacity to self-manage their condition
- Improve medication management and reconciliation
- Improve health indicators for chronically ill patients including those with mental health and substance abuse disorders
- Reduce avoidable acute care utilization (readmissions, admissions & ED visits)
- Improve patient experience

### Core Components

Participating PRIME entities undertaking this project may complete the following components:

1. Develop a complex care management program at one site or with one defined cohort, or expand an existing program from a pilot site to all sites or to additional high-risk groups and demonstrate engagement of patients in the design and implementation of the project.

2. Utilize at least one nationally recognized complex care management program methodology.\(^{59}\)

3. Identify target population(s) and develop program inclusion criteria based on quantitative and qualitative data (e.g., acute care utilization, lack of primary care utilization, number of high-risk medical mental or SUD conditions, polypharmacy, primary care input, functional status, patient activation, social support or other factors). Include patient factors associated with a higher probability of being impacted by complex care management.

4. Conduct a qualitative assessment of high-risk, high-utilizing patients.

5. Establish data analytics systems using clinical (e.g., EHR, registries), utilization and other available data (e.g., financial, health plan, zip codes), to enable identification of high-risk/rising risk patients for targeted complex care management interventions, including ability to stratify impact by race, ethnicity and language.

6. Develop a multi-disciplinary care team, to which each participant is assigned, that is tailored to the target population and whose interventions are tiered according to patient level of risk.

7. Ensure that the complex care management team has ongoing training, coaching, and monitoring towards effective team functioning and care management skill sets.

8. Implement evidence-based practice guidelines to address risk factor reduction (smoking cessation/immunization/substance abuse identification and referral to treatment/depression and other behavioral health screening/etc.) as well as to ensure appropriate management of chronic diseases:
   a. Use standardized patient assessment and evaluation tools (may be developed locally, or adopted/adapted from nationally recognized sources\(^{60}\))
   b. Use educational materials that are consistent with cultural, linguistic and health literacy needs of the target population.

---

\(^{59}\) see The Commonwealth Fund, California Quality Collaborative, Camden Coalition, IHI and The Center for Health Care Strategies Super Utilizer Summit and Policy Brief

\(^{60}\) e.g., PHQ-9, HARMS-8, Patient Activation Measure, AHRQ Whole Person Care Assessment Tool
### Project Domain

**Domain 2: Targeted High-Risk Or High-Cost Populations**

### Project Title

2.3 Complex Care Management for High-Risk Medical Populations

9. Ensure systems and culturally appropriate team members (e.g. community health worker, health navigator or promotora) are in place to support system navigation and provide patient linkage to appropriate physical health, mental health, SUD and social services. Ensure follow-up and retention in care to those services, which are under DPH/DMPH authority, and promote adherence to medications.

10. Implement technology-enabled data systems to support patients and care teams throughout the care management program including patient identification, pre-visit planning, point-of-care delivery, care plan development and population/panel management activities.

11. Implement a data-driven system for rapid cycle improvement and performance feedback to address quality and safety of patient care, which includes patients, front line staff and senior leadership.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Care Coordinator Assignment</td>
<td>N/A</td>
<td>*University of Washington/Coordinated Care Initiative</td>
</tr>
<tr>
<td>Medication Reconciliation – 30 days</td>
<td>0097</td>
<td>NCQA</td>
</tr>
<tr>
<td>Prevention Quality Overall Composite PQI #90</td>
<td>N/A</td>
<td>AHRQ</td>
</tr>
<tr>
<td>Timely Transmission of Transition Record</td>
<td>0648</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>
4. **Project 2.4 Integrated Health Home for Foster Children**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.4 Integrated Health Home for Foster Children</td>
</tr>
</tbody>
</table>

### Rationale

Many of the 55,000 foster children in California are at risk of caretaker, food, housing, and health provider insecurity, or some combination thereof.\(^{61}\) These challenges lead to an increase in their medical, behavior and social needs. Over half of foster children demonstrate behavioral issues calling for mental health treatment, and 35% to 60% show signs of acute or chronic health condition.\(^{62}\) Provisions at the federal level in the ACA adopted in California are recent efforts to support this vulnerable population.

To provide the best care to foster children, an integrated health home offers important stability, improved primary care outcomes and timely specialty care. Under the health home model, DPH/DMPH would serve as a central entity to facilitate connections between the patient and the medical, behavioral, social and legal entities operating in a foster child’s life would increase case continuity and remove system inefficiencies.

An integrated health home, including medication management and integrated behavioral health, would also be a tool used to reduce the inappropriate use of psychotropic medications for foster children, which have been found to be prescribed without accompanying mental health treatment, in high doses, and to very young children.\(^{63}\) Foster children are found to receive psychotropic medication in 16% to 23% of cases, compared to 5% to 6% of children on Medicaid.\(^{64}\)

PRIME investments in an integrated health home of the foster child population would provide opportunities for early identification of risk factors, improved medication management and treatment plan continuity and engagement with caretakers that will best improve this population’s quality of care.

### Goals/Objectives

To implement integrated health homes for children in the Department of Children Youth and Families foster system. Provide foster children with a “one-stop-shop” for fully integrated health services including physical and behavioral health, as well as needed substance abuse and social services. Improve the overall quality of care for foster children within the development and implementation of a patient centered medical home.

Specific objectives include:

- Improve care coordination for foster youth and their families

---

\(^{61}\) California Child Welfare Indicators Project. http://cssr.berkeley.edu/ucb_childwelfare/


\(^{64}\) Ibid.
<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.4 Integrated Health Home for Foster Children</td>
</tr>
<tr>
<td></td>
<td>• Improve patient adherence to their treatment regimen</td>
</tr>
<tr>
<td></td>
<td>• Improved communication and documentation of communication and coordination with child welfare services</td>
</tr>
<tr>
<td></td>
<td>• Reduce avoidable acute care utilization (ER, admissions)</td>
</tr>
<tr>
<td></td>
<td>• Improve patient experience</td>
</tr>
</tbody>
</table>

### Core Components

Participating PRIME entities undertaking this project may complete the following components:

1. Develop or expand a multi-therapeutic support model whereby PCPs working in Public Healthcare Systems receive support in the ongoing management and treatment of foster children:
   a. Demonstrate engagement of patients and families in the design and implementation of this project.

2. Implement a physical-behavioral health integration program that utilizes a nationally-recognized model (e.g., the Four Quadrant Model for Clinical Integration).

3. Multi-therapeutic care team will:
   a. Identify patient risk factors using a combination of qualitative and quantitative information.
      Complete a patient needs assessment using a standardized questionnaire
   b. Collaborate on evidence-based standards of care including medication management, care coordination and care engagement process.
   c. Implement multi-disciplinary case conferences/consults on patients with complex needs.
   d. Ensure the development of a single Treatment Plan that includes the patient’s behavioral health issues, medical issues, substance abuse and social needs:
      i. Use of individual and group peer support.
   e. Develop processes for maintaining care coordination and “system continuity” for foster youth who have one or more changes in their foster home.
   f. Ensure that the Treatment Plan is maintained in a single shared EHR/clinical record that is accessible across the treatment team to ensure coordination of care planning.
   g. Assess and provide care for all routine pediatric issues with a specific focus on:
      i. Mental health/toxic stress
      ii. Obesity
      iii. Chronic disease management
      iv. Medication/care plan adherence which are vulnerable when kids transition care givers frequently
      v. Substance abuse issues

4. Implement technology-enabled data systems to support pre-visit planning, point-of-care delivery, population/panel management activities and care coordination. Timely, relevant and actionable data is used to support patient engagement, and drive clinical, operational and strategic decisions including continuous QI activities.

5. Provide linkages to needed services that at a minimum includes child welfare agency, mental health, substance abuse and public health nursing as well as any other social services that are necessary to meet patient needs in the community.
### Project Domain
Domain 2: Targeted High-Risk Or High-Cost Populations

### Project Title
2.4 Integrated Health Home for Foster Children

<table>
<thead>
<tr>
<th>Required Project Metrics</th>
<th>NQF#</th>
<th>Measure Steward</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescent Well-Care Visit</td>
<td>N/A</td>
<td>NCQA</td>
</tr>
<tr>
<td>Developmental Screening in the First Three Years of Life</td>
<td>1448</td>
<td>NCQA</td>
</tr>
<tr>
<td>Documentation of Current Medications in the Medical Record (0-18 yo)</td>
<td>Variation on 0419</td>
<td>CMS</td>
</tr>
<tr>
<td>Screening for Clinical Depression and follow-up</td>
<td>0418</td>
<td>CMS</td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling (13 yo and older)</td>
<td>Variation on 0028</td>
<td>AMA-PCPI</td>
</tr>
<tr>
<td>Well Child Visits - First 15 months of life</td>
<td>1392</td>
<td>NCQA</td>
</tr>
<tr>
<td>Well Child Visits - Third, Fourth, Fifth, and Sixth Years of life</td>
<td>1516</td>
<td>NCQA</td>
</tr>
</tbody>
</table>
5. **Project 2.5 Transition to Integrated Care: Post Incarceration**

<table>
<thead>
<tr>
<th><strong>Project Domain</strong></th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Project Title</strong></td>
<td>2.5 Transition to Integrated Care: Post Incarceration</td>
</tr>
</tbody>
</table>
| **Rationale**      | Incarcerated populations have much higher prevalence of serious medical and behavioral health conditions than the non-incarcerated population. In light of the significant health needs of formerly incarcerated Californians, this project is designed to ensure a well-planned transition into the public health care system for former inmates. Release from incarceration represents a significant public health opportunity to continue treatment of critical conditions, increase engagement of former inmates and drive down avoidable health care costs.  

For the 130,000 individuals leaving a California prison each year, transitioning into society from incarceration presents an opportunity to promote health care enrollment, interaction with medical providers, and coordination of other social services. A community health worker-led care management program reduced ED utilization through increasing primary care engagement with individuals transitioning from prison. The San Francisco-based Transitions Clinic, a community health center focused on transitional health care services, has shown increased patient engagement through medical care and coordinated support with services such as assistance with housing, jobs, legal aid, substance abuse counseling, health care system navigation, and chronic disease self-management support. By incorporating these evidence-based approaches, proposed PRIME initiatives would utilize community health workers and leverage partnerships with prisons, jails, social services and housing to create seamless transitions and improved care for these recently released populations.  

<table>
<thead>
<tr>
<th><strong>Goals/Objectives</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>To improve the transition of care for the recently incarcerated, from the criminal justice system to the public health care system. Increase rates of enrollment into coverage, successfully establish care with, and coordination between, primary care, and appropriate behavioral health, substance use and social services, reduce avoidable acute care utilization, and improve the immediate and long-term health of the patients.</strong></td>
<td></td>
</tr>
<tr>
<td>Specific objectives include:</td>
<td></td>
</tr>
<tr>
<td>- Increase enrollment into health coverage</td>
<td></td>
</tr>
<tr>
<td>- Improve establishment of, and engagement with, primary care, the local public health department, and coordination with behavioral health care and necessary social services</td>
<td></td>
</tr>
<tr>
<td>- Improve health indicators for patients with chronic condition(s)</td>
<td></td>
</tr>
<tr>
<td>- Decrease preventable acute care utilization</td>
<td></td>
</tr>
</tbody>
</table>

---

65 Gorenstein, D. “In prison you get health care. When you're released ... “ 30 December 2013. Marketplace.org  
### Project Domain
Domain 2: Targeted High-Risk Or High-Cost Populations

### Project Title
2.5 Transition to Integrated Care: Post Incarceration

- Link patients to necessary social services for housing, employment and other services to reduce risk of recidivism

### Core Components
Participating PRIME entities undertaking this project may complete the following components:

1. Develop a care transitions program for those individuals who have been individuals sentenced to prison and/or jail that are soon-to-be released/or released in the prior 6 months who have at least one chronic health condition and/or over the age of 50.
2. Develop processes for seamless transfer of patient care upon release from correctional facilities, including:
   a. Identification of high-risk individuals (e.g., medical, behavioral health, recidivism risk) prior to time of release
   b. Ongoing coordination between health care and correctional entities (e.g., parole/probation departments)
   c. Linkage to primary care medical home at time of release
   d. Ensuring primary care medical home has adequate notification to schedule initial post-release intake appointment and has appropriate medical records prior to that appointment, including key elements for effective transition of care
   e. Establishing processes for follow-up and outreach to individuals who do not successfully establish primary care following release
   f. Establishing a clear point of contact within the health system for prison discharges.
3. Develop a system to increase rates of enrollment into coverage and assign patients to a health home, preferably prior to first medical home appointment.
4. Health System ensures completion of a patient medical and behavioral health needs assessment by the second primary care visit, using a standardized questionnaire including assessment of social service needs. Educational materials will be utilized that are consistent with cultural and linguistic needs of the population.
5. Identify specific patient risk factors which contribute to high medical utilization
   a. Develop risk factor-specific interventions to reduce avoidable acute care utilization.
6. Provide coordinated care that addresses co-occurring mental health, substance use and chronic physical disorders, including management of chronic pain.
7. Identify a team member with a history of incarceration (e.g., community health worker) to support system navigation and provide linkages to needed services if the services are not available within the primary care home (e.g., social services and housing) and are necessary to meet patient needs in the community.
8. Evidence-based practice guidelines will be implemented to address risk factor reduction (e.g., immunization, smoking cessation, screening for HCV, trauma, safety, and overdose risk, behavioral health screening and treatment, individual and group peer support) as well as to ensure appropriate management of chronic diseases (e.g., Asthma, Cardiovascular Disease, COPD, Diabetes).
9. Develop processes to ensure access to needed medications, DME or other therapeutic services (dialysis, chemotherapy) immediately post-incarceration to prevent interruption of care and subsequent avoidable use of acute services to meet those needs.
10. Engage health plan partners to pro-actively coordinate Long Term Care services prior to
### Project Domain
Domain 2: Targeted High-Risk Or High-Cost Populations

### Project Title
2.5 Transition to Integrated Care: Post Incarceration release for timely placement according to need.

11. Establish or enhance existing data analytics systems using health, justice and relevant community data (e.g., health plan), to enable identification of high-risk incarcerated individuals for targeted interventions, including ability to stratify impact by race, ethnicity and language.

12. Implement technology-enabled data systems to support pre-visit planning, point-of-care delivery, population/panel management activities, care coordination, and patient engagement, and to drive operational and strategic decisions including continuous QI activities.

13. To address quality and safety of patient care, implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff, and senior leadership.

14. Improve staff engagement by:
   a. Implementing a model for team-based care in which staff performs to the best of their abilities and credentials
   b. Providing ongoing staff training on care model
   c. Involving staff in the design and implementation of this project.

15. Engage patients and families using care plans, and self-management education, including individual and group peer support, and through involvement in the design and implementation of this project.

16. Participate in the testing of novel metrics for this population.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Drug Misuse (SBIRT)</td>
<td>N/A</td>
<td>Oregon CCO</td>
</tr>
<tr>
<td>Controlling Blood Pressure</td>
<td>0018</td>
<td>NCQA</td>
</tr>
<tr>
<td>Prevention Quality Overall Composite #90</td>
<td>N/A</td>
<td>AHRQ</td>
</tr>
<tr>
<td>Screening for Clinical Depression and follow-up</td>
<td>0418</td>
<td>CMS</td>
</tr>
<tr>
<td>Tobacco Assessment and Counseling</td>
<td>0028</td>
<td>AMA-PCPI</td>
</tr>
</tbody>
</table>
6. **Project 2.6 Chronic Non-Malignant Pain Management**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.6 Chronic Non-Malignant Pain Management</td>
</tr>
</tbody>
</table>

**Rationale**

Thirty-four million Americans suffer from chronic non-malignant pain (CNMP), defined as pain lasting six months or more unrelated to cancer that does not respond to conventional medical treatment. The high prevalence of CNMP results in annual total costs of $85 to $90 billion in the United States, including medical costs and loss in productivity.\(^6^8\) For patients, risks include pain from failure to get treatment, possible addiction to prescribed medication and a high risk of depression and/or suicide from untreated pain.

Over the last decade deaths involving opioid analgesics has more than tripled, with the majority of those deaths due to prescription drugs.\(^6^9\) Opiates were the most commonly involved medication although often these were used in combination with other drugs. Drug-related deaths in the U.S. each year now exceed those due to motor vehicle accidents. However, it is equally clear that a significant number of individuals have severe, non-malignant, chronic pain that may even be disabling. Thus, there is a pressing need in the health care system to address the needs of these chronic pain patients using interventions recognize current or potential substance abuse disorders and can maximize benefit while minimizing risk and potential side effects.

Research on effective pain management supports a multi-modal approach, incorporating physical and occupational therapy and other complementary disciplines.\(^7^0\) Participating PRIME entities can best provide high-quality care to these patients through the adoption of evidence-based protocols and guidelines employing non-pharmacologic treatment. Additionally, training on these new processes should be provided to educate and engage clinicians and non-clinical staff. The proposed PRIME project incorporates these modified protocols and guidelines as system re-design to better manage patients’ pain.

**Goals/Objectives**

To improve primary care providers’ and care teams’ ability to identify, and manage chronic non-malignant pain using a function-based, multimodal approach, and to improve outcomes by distinguishing between, and implementing appropriate care plans, for patients who will benefit from opioids and patients who are likely to be harmed by them.

Specific objectives include:

- Improve the function and/or health related quality of life of patients age 18 years and older with chronic pain.

---


\(^{70}\) Ibid.
<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.6 Chronic Non-Malignant Pain Management</td>
</tr>
</tbody>
</table>

- Improve the assessment and reassessment of patients age 18 years and older with chronic pain diagnosis utilizing the biopsychosocial model.
- Improve the use of multi-modal pain management strategies, including but not limited to physical and occupational therapy, group or individual psychotherapy/counseling, and other complementary and alternative therapies for patients age 18 years and older with chronic pain.
- Develop safe and effective prescribing practices for providers caring for patients age 18 years and older with chronic pain.
- Improve the effective use of non-opioid medications in the management of patients age 18 years and older with chronic pain.
- Improve the rate of identification and treatment of prescription opioid use disorders in primary care patients age 18 and older with a diagnosis of chronic pain.
- Decrease the rate of opioid prescriptions for adults 18 years and older who have ongoing substance abuse and/or diagnoses that do not warrant opioids (e.g., fibromyalgia, neuropathy, headache, sore throat, uncomplicated neck and back pain, uncomplicated musculoskeletal pain, non-traumatic tooth pain).
- Decrease the rate of ED visits/acute care utilization related to opioid overdose of patients age 18 years and older with chronic pain.
- Increase access to naloxone for patients with chronic opioid prescriptions.

**Core Components (key elements)**

Participating PRIME entities undertaking this project may complete the following components:

1. Develop an enterprise-wide Chronic Non-Malignant Pain management strategy.
2. Demonstrate engagement of patients in the design and implementation of the project.
3. Implement or adapt a state or nationally recognized methodology\(^71\) for the assessment and management of chronic pain.
4. Implement protocols for primary care management of patients with chronic pain including:
   a. A standard standardized Pain Care Agreement
   b. Standard work and policies to support safe prescribing practices
   c. Comprehensive pain history including psycho/social evaluation, functional evaluations, care plan, pain medication risk/benefit informed consents, ongoing monitoring of plan/outcomes (e.g., use of standardized monitoring template for follow-up visits for CNP), aberrant behavior screening and management protocols
   d. Guidelines regarding maximum acceptable dosing.
5. Provide culturally, linguistically and literacy level-appropriate patient education on the pathology of chronic pain, rationale for rehabilitation and expected goals of treatment.
6. Coordinate a chronic pain care team that minimally consists of a physician champion and medical support staff. Suggestions for care clinicians from other disciplines include occupational and physical therapy, behavioral health, pharmacy, substance use disorder

\(^{71}\) Institute for Clinical Systems Improvement, Medical Board of California September 2014 (DRAFT) Guidelines for Prescribing Controlled Substances for Pain, The American Pain Society, or The American Society of Anesthesiologists
### Project Domain

<table>
<thead>
<tr>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
</table>

### Project Title

2.6 Chronic Non-Malignant Pain Management

- specialists, neurology, occupational medicine, anesthesiology/pain management, home care, social work, and physical medicine and rehabilitation.

7. Implement technology-enabled data systems to support pre-visit planning, point of care delivery, and team based population/panel management and care coordination.

8. Determine population ICD-9/ICD-10 codes for data collection that is unique to patients with chronic pain on opioids and develop a registry for pain assessments, care agreements, medication refill standing orders and urine toxicology screening.

9. Utilize provider activity report card to provide feedback to providers on how their chronic pain management practice compares to peers and benchmarks.

10. Establish a policy for monitoring and maintaining opioid agreements for prescription refills with other clinics, pharmacies, dentists and specialists.

11. Develop a process for scheduling pain focused follow-up patient visits to ensure that patients receive refills in a timely manner while also receiving recommended monitoring for signs of diversion or misuse.

12. Develop staff and clinician training regarding the organization’s process for managing patients with chronic non-malignant pain.

13. Train providers to identify signs of prescription opioid use disorders and provide treatment options for patients diagnosed with opioid use disorders, including suboxone treatment, referral to methadone maintenance, referral to inpatient and outpatient substance use disorder treatment facilities, and referral to needle exchanges.

14. Develop and implement protocols for prescribing naloxone to patients receiving opioids for chronic pain.

15. Identify standardized multidimensional pain assessment, functional assessment, psychological assessment\(^ {72}\), and opioid assessment tools\(^ {73}\) that meet the needs of the care clinicians and are appropriate for the patient populations.

16. Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership. Timely, relevant and actionable data is used to support patient engagement, and drive clinical, operational and strategic decisions including continuous QI activities.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Drug Misuse (SBIRT)</td>
<td>N/A</td>
<td>Oregon CCO</td>
</tr>
</tbody>
</table>

---

\(^{72}\) Examples of pain assessment, functional assessment, and psychological assessment tools are, but are not limited to: Brief Pain Inventory (BPI), Physical Functional Ability Questionnaire (FAQ5), Oswestry Low Back Disability Index, PHQ-9, GAD 7

\(^{73}\) Examples of opioid and substance abuse assessment tools are, but are not limited to:CAGE and CAGE-AID, Webster's Opioid Risk Tool (ORT), DIRE Tool, Screener and Opioid Assessment for Patients in Pain (SOAPP®), Current Opioid Misuse Measure (COMMTM), Prescription Drug Use Questionnaire (PDUQ), Screening Tool for Addiction Risk (STAR), Screening Instrument for Substance Abuse Potential (SISAP), Pain Medicine Questionnaire (PMQ), Audit-C, Screening, Brief Intervention, Referral to Treatment (SBIRT)
<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domain 2: Targeted High-Risk Or High-Cost Populations</td>
<td>2.6 Chronic Non-Malignant Pain Management</td>
</tr>
<tr>
<td>Assessment and Management of Chronic Pain:</td>
<td>Patients with chronic pain prescribed an opioid who have an opioid agreement form and an annual urine toxicology screen</td>
</tr>
<tr>
<td>Patients with chronic pain on long term opioid</td>
<td>Patients with chronic pain prescribed an opioid who have an opioid agreement form and an annual urine toxicology screen</td>
</tr>
<tr>
<td>therapy checked in PDMPs</td>
<td>Screening for Clinical Depression and follow-up</td>
</tr>
<tr>
<td>Treatment of Chronic Non-Malignant Pain with</td>
<td>Treatment of Chronic Non-Malignant Pain with Multi-Modal Therapy</td>
</tr>
</tbody>
</table>
7. **Project 2.7 Comprehensive Advanced Illness Planning and Care**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 2: Targeted High-Risk Or High-Cost Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>2.7 Comprehensive Advanced Illness Planning and Care</td>
</tr>
<tr>
<td>Rationale</td>
<td></td>
</tr>
</tbody>
</table>

Palliative care and end of life planning have the potential to increase quality of life for those most in need of sensitive, cohesive care. Only 20 percent of potentially appropriate patients have access to community-based palliative care services, according to an estimate by the Berkeley Forum.\(^{74}\) Crucial to improving quality of life for patients with chronic or terminal illnesses is ensuring smooth transitions of care, and excellent care in every setting, including hospitals, skilled nursing facilities, and home-based environments.

Several concurrent statewide end of life care programs and initiatives exist with the goal to increase quality of end of life care. PRIME hospitals should participate in these statewide initiatives as they address patient needs at the most sensitive time of life.

These statewide programs and initiatives include:

- **Senate Bill 1004 (Hernandez):** This legislation, enacted in September 2014 and effective January 1, 2015, directs DHCS to establish standards, impart quality metrics, and provide technical assistance to Medi-Cal managed care plans to ensure delivery of palliative care services, including hospice benefits.
- **Health Homes for Complex Patients Initiative:** This effort, in part, aims to identify patients in hospitals, long-term care facilities, or the community, who may benefit from and have a desire for palliative care services, and offer them comprehensive palliative care by people who are trained in this area.
- **Statewide Physician Orders for Life-Sustaining Treatment (POLST) registry:** The California Healthcare Foundation is coordinating an effort to establish a statewide POLST registry, and is currently planning a pilot project to test the registry. Several states have had initial success creating and maintaining a successful registry.

---

Project Domain | Domain 2: Targeted High-Risk Or High-Cost Populations
---|---
Project Title | 2.7 Comprehensive Advanced Illness Planning and Care

- Let’s Get Healthy California (LGHC): There are several end of life care measures selected for LGHC, including: Terminal hospital stays that include intensive care unit days, percent of California hospitals providing in-patient palliative care, hospice enrollment rate, and advance care planning.

**Goals/Objectives**

To ensure access to comprehensive care in alignment with patient preferences in hospital and community settings for all patients facing advanced illness.

Specific objectives include:

- Increase timely access to ambulatory and inpatient palliative care services
- Introduction of Primary and/or Specialty Palliative Care services at time of diagnosis of advanced illness
- Relieve pain and other distressing symptoms
- Improve quality of life for both the patient and the family
- Improve concordance between patient/family preference and provision of care
- Reduce avoidable acute care utilization

**Core Components**

Participating PRIME entities undertaking this project may complete the following components:

1. Establish or expand both ambulatory and inpatient palliative care programs that provide:
   a. Total, active and individualized patient care, including comprehensive assessment, inter-professional care planning and care delivery
   b. Support for the family
   c. Interdisciplinary teamwork
   d. Effective communication (culturally and linguistically appropriate)
   e. Effective coordination
   f. Attention to quality of life and reduction of symptom burden
   g. Engagement of patients and families in the design and implementation of the program.

2. Develop criteria for program inclusion based on quantitative and qualitative data:
   a. Establish data analytics systems to capture program inclusion criteria data elements.

3. Implement, expand, or link with, a Primary Palliative Care training program for frontline clinicians to receive basic PC training, including Advanced Care Planning, as well as supervision from specialty PC clinicians.
   a. Assure key palliative care competencies for primary care providers by mandating a minimum of 8 hours of training for front line clinicians in communication skills and symptom management

4. Develop comprehensive advance care planning processes and improve implementation of advance care planning with advanced illness patients.

5. Establish care goals consistent with patient and family preferences, and develop protocols for management/control of pain and other symptoms in patients with advanced
illness, including a holistic approach that includes spiritual and emotional needs.

6. Improve completion of POLST with eligible patients and participate in the state-wide POLST registry.

7. Provide access to clinical psychologist on the Palliative care team to address psychological needs of patient and the family members during the advanced illness and provide grief counseling and support to the family after death of their loved ones.

8. Enable concurrent access to hospice and curative-intent treatment, including coordination between the providing services.

9. Develop partnerships with community and provider resources including Hospice to bring the palliative care supports and services into the practice, including linkage with PC training program.

10. For advanced illness patients transitioning between primary care, hospital, skilled nursing facilities (SNFs), and/or home-based environments, ensure that the advance care plan is clearly documented in the medical record and transmitted in a timely manner to the receiving facilities and care partners who do not have access to the health system’s medical record.

11. Engage staff in trainings to increase role-appropriate competence in palliative care skills, with an emphasis on communication skills.

12. Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advance Care Plan</td>
<td>0326</td>
<td>NCQA</td>
</tr>
<tr>
<td>Ambulatory Palliative Care Team Established</td>
<td>N/A</td>
<td>*University of California, San Francisco (UCSF)</td>
</tr>
<tr>
<td>MWM#8 - Treatment Preferences (Inpatient)</td>
<td>1641</td>
<td>UNC Chapel Hill</td>
</tr>
<tr>
<td>MWM#8 - Treatment Preferences (Outpatient)</td>
<td>N/A</td>
<td>*University of California, San Francisco (UCSF)</td>
</tr>
<tr>
<td>Palliative Care Service Offered at Time of Diagnosis of Advanced Illness</td>
<td>N/A</td>
<td>*University of California, San Francisco (UCSF)</td>
</tr>
<tr>
<td>Proportion Admitted to Hospice for Less than 3 Days</td>
<td>0216</td>
<td>ASCO</td>
</tr>
</tbody>
</table>
C. Domain 3: Resource Utilization Efficiency
Minimum of One Project Required for DPHs

Projects in Domain 3 will reduce unwarranted variation in the use of evidence-based, diagnostics and treatments (antibiotics, blood or blood products, and high cost imaging studies and pharmaceutical therapies) targeting overuse, misuse, as well as inappropriate underuse of effective interventions. Projects will also eliminate the use of ineffective or harmful targeted clinical services. Participating DPH systems must select at least one project in this domain.
1. **Project 3.1 Antibiotic Stewardship**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.1 Antibiotic Stewardship</td>
</tr>
</tbody>
</table>
| **Rationale**        | Proper use of antibiotics has become a pressing healthcare quality concern as antimicrobial resistance has been documented across several pathogens in increasing numbers throughout the United States. Infections resistant to antibiotic treatment put patient health at risk and also add to healthcare costs through extended patient treatment. The CDC has identified antibiotic stewardship as a key strategy to combat pathogen resistance through incorporating best clinical practices based on antibiotic dosing, duration and route. For participating PRIME entities, a stewardship program can be implemented through policies and procedures, training, and a reporting system. In addition to reducing resistance, promoting antimicrobial stewardship has proven to lower costs, minimize medication-based adverse events and improve patient quality of care.

California continues to be the sole state with legislation passed targeting antimicrobial stewardship. Participating PRIME entities can participate in learning forums such as the Antimicrobial Stewardship Program Collaborative facilitated by the California Department of Public Health, to continue the cross-pollination of best practices.

| **Goals/Objectives** | To improve the appropriate use of antimicrobials by reducing overall antibiotic use for non-bacterial diseases, and optimizing antibiotic use for bacterial infections, with a special emphasis on agents with broad spectrum activity, in order to improve patient outcomes and eliminate unnecessary patient care costs. Specific objectives include:

- Reduce broad-spectrum antibiotic use
- Decrease inappropriate use of antibiotics across hospital and health care system
- Reduce hospital associated Clostridium difficile infections

| **Core Components** | Systems undertaking this project may complete the following components:

1. Utilize state and/or national resources to develop and implement an antibiotic stewardship program, such as the California Antimicrobial Stewardship Program Initiative, or the IHI-CDC 2012 Update “Antibiotic Stewardship Driver Diagram and Change Package”

---

75 Infection Control and Hospital Epidemiology, Vol. 33, No. 4, Special Topic Issue: Antimicrobial Stewardship (April 2012), pp. 322-327
77 The Change Package notes: “We do not recommend that any facility attempt to implement all of the interventions at once. There are a large number of interventions outlined in the Change Package, and attempting to implement too many at one time will likely create
### Project Domain

**Domain 3: Resource Utilization Efficiency**

<table>
<thead>
<tr>
<th>Project Title</th>
<th>3.1 Antibiotic Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Demonstrate engagement of patients in the design and implementation of the project.</td>
</tr>
<tr>
<td>2.</td>
<td>Develop antimicrobial stewardship policies and procedures.</td>
</tr>
<tr>
<td>3.</td>
<td>Participate in a learning collaborative or other program to share learnings, such as the “Spotlight on Antimicrobial Stewardship” programs offered by the California Antimicrobial Stewardship Program Initiative.</td>
</tr>
<tr>
<td>4.</td>
<td>Create standardized protocols for ordering and obtaining cultures and other diagnostic tests prior to initiating antibiotics.</td>
</tr>
<tr>
<td>5.</td>
<td>Develop a method for informing clinicians about unnecessary combinations of antibiotics.</td>
</tr>
<tr>
<td>6.</td>
<td>Based on published evidence, reduce total antimicrobial Days of Therapy (DOT) by providing standards and algorithms for recommended agents by disease type, focusing on short course regimens (e.g., 3-5 days of therapy for uncomplicated cystitis, 7 days for uncomplicated pyelonephritis, 5-7 days for uncomplicated non-diabetic cellulitis, 5 day therapy for community acquired pneumonia (CAP), 7-8 days for therapy for VAP or hospital acquired pneumonia).</td>
</tr>
<tr>
<td>7.</td>
<td>Develop evidence-based CPOE algorithms and associated clinician training, to support antibiotic stewardship choices during order entry. These could include approaches such as guidelines for duration of antibiotics, within drug class auto-switching for specific antibiotics and doses, or restriction of specific antibiotics at the point of ordering (e.g., broad spectrum agents).</td>
</tr>
<tr>
<td>8.</td>
<td>Implement stewardship rounds focusing on high yield drugs to promote de-escalation after the drugs are started, such as regular antibiotic rounds in the ICU.</td>
</tr>
<tr>
<td>9.</td>
<td>Improve diagnostic and de-escalation processes to reduce unnecessary antibiotic use based upon length of therapy or antibiotic spectrum, such as:</td>
</tr>
<tr>
<td>a.</td>
<td>Procalcitonin as an antibiotic decision aid</td>
</tr>
<tr>
<td>b.</td>
<td>Timely step-down to oral antibiotic therapy to support early discharge from the hospital for acute infections</td>
</tr>
<tr>
<td>c.</td>
<td>Use of oral antibiotics for osteomyelitis to reduce prolonged IV exposures.</td>
</tr>
<tr>
<td>10.</td>
<td>Evaluate the use of new diagnostic technologies for rapid delineation between viral and bacterial causes of common infections.</td>
</tr>
<tr>
<td>11.</td>
<td>Adopt the recently described &quot;public commitment&quot; strategy in outpatient clinics to encourage providers not to prescribe antibiotics for URIs.</td>
</tr>
<tr>
<td>12.</td>
<td>Publish organization-wide provider level antibiotic prescribing dashboards with comparison to peers and benchmarks. Contribute system level data for a similar dashboard across all public health care systems.</td>
</tr>
<tr>
<td>13.</td>
<td>Implement a system a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.</td>
</tr>
</tbody>
</table>

huge challenges. Rather, the Change Package is meant to serve as a menu of options from which facilities can select specific interventions to improve antibiotic use.” (p. 1, Introduction).

78 Launched in February 2010, this statewide antimicrobial stewardship program expands use of evidenced-based guidelines to prevent and control infections and improve patient outcomes: [http://www.cdph.ca.gov/programs/hai/Pages/AntimicrobialStewardshipProgramInitiative.aspx](http://www.cdph.ca.gov/programs/hai/Pages/AntimicrobialStewardshipProgramInitiative.aspx).
<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.1 Antibiotic Stewardship</td>
</tr>
<tr>
<td>Required Project Metrics</td>
<td></td>
</tr>
<tr>
<td>Measure name</td>
<td>NQF#</td>
</tr>
<tr>
<td>Avoidance of antibiotic treatment in adults with acute bronchitis</td>
<td>0058</td>
</tr>
<tr>
<td>Avoidance of Antibiotic Treatment with Low Colony Urinary Cultures</td>
<td>N/A</td>
</tr>
<tr>
<td>National Healthcare Safety Network (NHSN) Antimicrobial Use Measure</td>
<td>2720</td>
</tr>
<tr>
<td>Prophylactic antibiotics discontinued at time of surgical closure</td>
<td>N/A</td>
</tr>
<tr>
<td>Reduction in Hospital Acquired Clostridium Difficile Infections</td>
<td>N/A</td>
</tr>
</tbody>
</table>
2. **Project 3.2 Resource Stewardship: High-Cost Imaging**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.2 Resource Stewardship: High-Cost Imaging</td>
</tr>
<tr>
<td>Rationale</td>
<td>Over-ordering diagnostic tests increases healthcare costs, inefficiency for patients, and produces no valuable clinical information. Imaging studies represent a very high percentage of these tests. The Choosing Wisely initiative, a joint effort between the American Board of Internal Medicine Foundation and <em>Consumer Reports</em>, produced a series of evidence-based recommendations for certain tests identified as overused. Participating PRIME entities will incorporate learnings from the Choosing Wisely program, as well as other resources like the American College of Radiology’s Appropriateness Criteria, in creating their own imaging management program meant to combat imaging overuse and misuse. Elements of the program will include established standards of care, data capacity improvements and the incorporation of cost information into the decision making process.</td>
</tr>
</tbody>
</table>

**Goals/Objectives**

To implement evidence based and population resource stewardship approaches to the use of high-cost imaging services, in order to reduce inappropriate utilization of imaging, and increase the amount of cost-effective and evidence based imaging performed in the system of care.

“The right study for the right patient at the right time”

Specific objectives include:

- Reduce the number of unnecessary/inappropriate studies
- Improve the use of evidence-based, lower cost imaging modalities when imaging is warranted

**Core Components**

Participating PRIME entities undertaking this project may complete the following components:

1. Implement an imaging management program, demonstrating engagement of patients in the design and implementation of components of the project.
2. Program should include identification of top imaging tests whose necessity should be assessed for possible overuse. Criteria for assessment could include:
   a. Frequency and cost of inappropriate/unnecessary imaging
      i. Appropriate Use: Beginning with state or nationally recognized models or guidelines (e.g., *American College of Radiology Appropriateness Criteria*, *American College of Cardiology Appropriate Use Criteria*) and incorporating pertinent local factors, programs will set out definitions for appropriateness
      ii. Cost: Programs will identify imaging studies associated with high costs due to high cost per study or high volume across the system
   b. Unwarranted practice variation within the participating DPHs/DMPHs

---

### Project Domain

<table>
<thead>
<tr>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
</table>

### Project Title

3.2 Resource Stewardship: High-Cost Imaging

c. Data completeness and ability to report the extent of a-c, building data capacity where needed
d. Whether there are established, tested and available evidence-based clinical pathways to
guide cost-effective imaging choices.

3. Establish standards of care regarding use of imaging, including:
   a. Costs are high and evidence for clinical effectiveness is highly variable or low.
   b. The imaging service is overused compared to evidence-based appropriateness criteria.
   c. Lack of evidence of additional value (benefits to cost) compared to other imaging options available to answer the clinical question.

4. Incorporate cost information into decision making processes:
   a. Develop recommendations as guidelines for provider-patient shared decision conversations in determining an appropriate treatment plan.
   b. Implementation of decision support, evidence-based guidelines and medical criteria to recommend best course of action

5. Provide staff training on project components including implementation of recommendations, and methods for engaging patients in shared decision making as regards to appropriate use of imaging.

6. Implement a system for continual rapid cycle improvement and performance feedback that includes patients, front line staff and senior leadership.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging for Routine Headaches (Choosing Wisely)</td>
<td>N/A</td>
<td>*Washington Health Alliance</td>
</tr>
<tr>
<td>Inappropriate Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism</td>
<td>0667</td>
<td>ACEP</td>
</tr>
<tr>
<td>Use of Imaging Studies for Low Back Pain</td>
<td>0052</td>
<td>NCQA</td>
</tr>
<tr>
<td>Use of Imaging Studies for Low Back Pain (red flags, no time limit)</td>
<td>N/A</td>
<td>*LAC Department of Health Services (variation on NQF 0052)</td>
</tr>
</tbody>
</table>
3. **Project 3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals**

<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals</td>
</tr>
</tbody>
</table>

**Rationale**

Expanded coverage under the Affordable Care Act has dramatically increased demand for prescription drugs in recent years. Nationwide, spending on prescription drugs reached $329.2 billion in 2013, up 3.2% from 2012.\(^{80}\) The recent surge in high-cost specialty drugs – popularly debated with the release an effective hepatitis C treatment costing $84,000 – is expected to further increase drug spending by 6.6% per year between 2015 and 2021.\(^{81}\) In response to rapid spending increases, payers and providers are gaining interest in resource stewardship programs that can curb unnecessary costs. These programs employ evidence-based strategies, such as utilization management, drug formularies, and prior authorization protocols.

Under the proposed PRIME project, participating PRIME entities will develop robust resource stewardship programs. The project will establish multidisciplinary teams of experts with committed time to monitor and contain drug costs. By investing in resource stewardship, the project has the potential to yield significant savings, transforming participating PRIME entities into more efficient, cost-effective providers of care.

**Goals/Objectives**

To implement evidence-based and population resource stewardship approaches to the use of high-cost pharmaceuticals. To guide clinician use of targeted therapies involving high-cost medications, develop decision analyses that include the impact of such treatments on the participating PRIME entity population in terms of health outcomes and the efficient use of available resources. Increase the use of decision support mechanisms for provider ordering of high-cost pharmaceuticals.

Specific objectives include:
- Increase appropriate use of high-cost pharmaceutical therapies
- Decrease inappropriate use of high-cost pharmaceutical therapies
- Improve use of shared decision making with patients
- Drive down health-care costs through improved use of targeted medications and prescribing behaviors
- Optimize 340b if eligible

**Core Components**

Participating PRIME entities undertaking this project may complete the following:

---


<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals</td>
</tr>
</tbody>
</table>

**components:**
1. Implement or expand a high-cost pharmaceuticals management program.
2. Implement a multidisciplinary pharmaceuticals stewardship team.
3. Develop a data analytics process to identify the participating PRIME entity highest cost pharmaceuticals (high-cost medications or moderate-cost meds with high prescribing volume). Identify high-cost medications whose efficacy is significantly greater than available lower cost medications.
   a. Using purchase price data, Identify the Top 20 medications and medication classes, focusing on the following: Analgesics, Anesthetics, Anticoagulants, Anti-Neoplastics, Diabetes, Hepatitis C, Immunoglobulins, Mental Health (Anti-Depressants/Sedatives/Anti-Psychotics), Respiratory (COPD/Asthma), Rheumatoid Arthritis
   i. **Exclude Anti-Infectives and Blood Products (addressed in separate PRIME Projects)**
4. Develop processes for evaluating impact of high-cost, high-efficacy drugs, particularly drugs to treat conditions (e.g., HCV) or to address circumstances (e.g., oral anticoagulants for patients without transportation for blood checks) more prevalent in safety net populations:
   a. Consider criteria that include ability of identified medications to improve patient health, improve patient function and reduce use of health care services.
5. Develop processes to impact prescribing by providers by establishing standards of care regarding prescribing of high cost pharmaceuticals, including:
   a. Use of decision support/CPOE, evidence-based guidelines and medical criteria to support established standards
   b. Develop processes to improve the appropriate setting for medication delivery including, transitioning pharmaceutical treatment to the outpatient setting wherever possible
   c. Promote standards for generic prescribing
   d. Promote standards for utilizing therapeutic interchange.
6. Improve the process for proper billing of medications, through clinician education and decision support processes.
7. Develop formulary alignment with local health plans.
8. Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership rapid cycle improvement using standard process improvement methodology.
9. Develop organization-wide provider level dashboards to track prescribing patterns for targeted high cost pharmaceuticals. Dashboard to include comparisons to peers and benchmarks. Contribute system level data for a similar dashboard across all public health care systems.
10. Develop processes for working with providers with prescribing patterns outside established standards, to identify and reduce barriers to meeting prescribing standards:
   a. Develop guidelines and provide staff training on methods for engaging patients in shared decision making for developing treatment plans within the context of the...
Project Domain | Domain 3: Resource Utilization Efficiency
---|---
Project Title | 3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals

11. Maximize access to 340b pricing:
   a. Share templates for contracting with external pharmacies
   b. To improve program integrity, share tools for monitoring of 340b contract compliance.

### Required Project Metrics

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherence to Medications</td>
<td>Variation on NQF 2467</td>
<td>*Alameda Health Systems (AHS)</td>
</tr>
<tr>
<td>Documentation of Current Medications in the Medical Record</td>
<td>0419</td>
<td>CMS</td>
</tr>
<tr>
<td>High-cost pharmaceuticals ordering protocols</td>
<td>N/A</td>
<td>*AHS</td>
</tr>
</tbody>
</table>
4. **Project 3.4 Resource Stewardship: Blood Products**

<table>
<thead>
<tr>
<th><strong>Project Domain</strong></th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Project Title</strong></td>
<td>3.4 Resource Stewardship: Blood Products</td>
</tr>
</tbody>
</table>

**Rationale**

Blood transfusions are one of the most common procedures performed in hospitals in the United States, but are also associated with significant risk for the patients.\(^{82}\) With over 15 million units of red blood cells transfused annually, quality organizations have focused on appropriate blood management as an area of massive opportunity to improve clinical outcomes through evidence-based standardization.

Through the implementation of a blood management program, participating PRIME entities will develop and streamline clinical processes, closely track clinical outcomes on dashboards and better manage blood products. Existing patient blood management methodologies, like those created by the Joint Commission, will be adopted locally, as will an interdisciplinary Transfusion Committee to drive change.

**Goals/Objectives**

To implement evidence-based approaches to the use of blood products. Increase use of decision support mechanisms for provider ordering of blood products to improve the safety and appropriateness of their use, with resultant improvements in health quality and resource utilization.

Specific objectives include:

- Promote reduced wastage of blood products that have been dispensed to the patient care area
- Promote reduced wastage of blood products that are in the hospital inventory but never get dispensed
- To identify, develop and promote the implementation of patient blood management (PBM) to improve appropriate use of blood and blood products by health providers.
- To improve clinical outcomes of transfusion and reduce adverse events from transfusion

**Core Components**

Participating PRIME entities undertaking this project may complete the following components:

1. Implement or expand a patient blood products management (PBM) program.
2. Implement or expand a Transfusion Committee consisting of key stakeholder physicians and medical support services, and hospital administration.
3. Utilize at least one nationally recognized patient blood management program methodology (e.g., The Joint Commission\(^{83}\), AABB)
4. Develop processes for evaluating impact of blood product use including appropriateness of

---


<table>
<thead>
<tr>
<th>Project Domain</th>
<th>Domain 3: Resource Utilization Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>3.4 Resource Stewardship: Blood Products</td>
</tr>
</tbody>
</table>

- **Domain 3: Resource Utilization Efficiency**

- **Project Title**: Resource Stewardship: Blood Products

- Use, adequacy of documentation, safety implications, cost, and departmental budget. Impact. Develop a data analytics process to track these and other program metrics.

- Establish standards of care regarding use of blood products, including:
  - Use of decision support/CPOE, evidence based guidelines and medical criteria to support and/or establish standards.

- Implement a system for continual performance feedback and rapid cycle improvement that includes patients, front line staff and senior leadership.

- Develop organization-wide dashboards to track provider level blood use patterns. Dashboard to include comparisons to peers and benchmarks. Contribute system level data for a similar dashboard across all public health care systems.

- Participate in the testing of novel metrics for PBM programs

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF#</th>
<th>Measure Steward (*Innovative metrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ePBM-01 Pre-op Anemia Screening, Selected Elective Surgical Patients</td>
<td>N/A</td>
<td>AABB/TJC (approval pending)</td>
</tr>
<tr>
<td>ePBM-02 Pre-op Hemoglobin Level, Selected Elective Surgical Patients</td>
<td>N/A</td>
<td>AABB/TJC</td>
</tr>
<tr>
<td>ePBM-03 Pre-op Type and Crossmatch, Type and Screen, Selected elective Surgical Patients</td>
<td>N/A</td>
<td>AABB/TJC</td>
</tr>
<tr>
<td>ePBM-04 Initial Transfusion Threshold</td>
<td>N/A</td>
<td>AABB/TJC</td>
</tr>
<tr>
<td>ePBM-05 Outcome of Patient Blood Management, Selected Elective Surgical Patients</td>
<td>N/A</td>
<td>AABB/TJC</td>
</tr>
</tbody>
</table>
Attachment II - PRIME Program Funding and Mechanics Protocol

I. Table of Contents

II. Preface ......................................................................................................................... 2

A. Public Hospital Redesign and Incentives in Medi-Cal ............................................. 2

B. PRIME Protocols ....................................................................................................... 2

III. Eligible Hospital Systems to Receive Funding ............................................................ 2

IV. PRIME Domains and Projects ................................................................................... 3

V. Key Elements of Five-Year PRIME Project Plans ....................................................... 4

VI. Plan Review and Approval Process ............................................................................ 5

A. DHCS Plan Approval Process .................................................................................... 5

B. Plan Modification Process .......................................................................................... 6

C. Metric Modification Process ...................................................................................... 7

VII. Allocation and Disbursement of Pool Funds .............................................................. 8

A. Total Available PRIME Incentive Payments for a DPH Five-Year PRIME Pool Plan... 8

Table 1: Total Computable PRIME Payments for DPHs ................................................. 9

B. Total Available PRIME Incentive Payments for a DMPH Five-Year PRIME .......... 10

Table 4: Total Computable PRIME Payments for DMPHs ............................................. 11

C. Payment Based on Metric Target Achievement ...................................................... 14

Table 6: Interim Mid-Year Metric Performance Achievement ....................................... 16

Table 7: Final Year-End Metric Performance Achievement ......................................... 16

D. Progress and Payment Reconciliation ...................................................................... 18

E. Reporting for Payment ............................................................................................... 18

F. Intergovernmental (IGT) Transfer Process ................................................................. 19

VIII. STATE REVIEW PROCESS ................................................................................ 19

IX. Reinvestment of Unallocated Funds ........................................................................ 20

A. Unused Pool Fund ....................................................................................................... 20

B. Unclaimed Pool Payment .......................................................................................... 20

Table 9: Unearned Claiming (for current DY) ................................................................. 21

X. Learning Collaboratives ............................................................................................ 25
II. Preface

A. Public Hospital Redesign and Incentives in Medi-Cal
On December 30, 2015, the Centers for Medicare and Medicaid Services (CMS) approved California’s request for a renewal to California’s section 1115(a) Medicaid demonstration (hereinafter “demonstration”) authorizing the creation of a Public Hospital Redesign and Incentives in Medi-Cal (hereinafter “PRIME”). This demonstration is approved through December 31, 2020. Paragraphs 70-103 of the Special Terms and Conditions (STCs) describe the general rules and requirements of PRIME.

B. PRIME Protocols
The PRIME requirements specified in the STCs are supplemented by the following attachments to the STCs:

- **Attachment D.** Designated Public Hospital Systems and District/Municipal Public Hospitals that are Participating PRIME entities
- **Attachment Q.** PRIME Projects and Metrics: This Attachment details the specific delivery system improvement activities (“projects”), including requirements regarding project metrics, that are eligible for PRIME funding; for each project, Attachment Q specifies the details of the projects, projects’ metrics, and metrics’ targets that will be the basis for earning PRIME incentive payments. Attachment Q also specifies the key elements of and the review and approval process for participating PRIME entities’ 5-year PRIME Project Plans. Participating PRIME entities will utilize this document for purposes of selecting projects (each of which specifies required metrics) to include in their 5-year PRIME Project Plans.
- **Attachment R.** Alternative Payment Methodologies: Attachment R will outline additional payment methodologies that will qualify as APM outside of the capitation payment methodologies.
- **Attachment S.** PRIME Evaluation and Monitoring: Attachment S will describe the state’s plan for meeting PRIME monitoring requirements as well as will include the final evaluation plan.
- **Attachment II.** PRIME Funding and Mechanics: Attachment II describes the general requirements for receiving incentive payments under PRIME, including the allocation, payment mechanisms and disbursement of pool funds; reporting requirements; and reinvestment of unallocated funds.

III. Eligible Hospital Systems to Receive Funding
As identified in Attachment D, designated public hospital (DPH) systems, (which include their affiliated governmental providers and contracted governmental and non-governmental entities as applicable), and District and Municipal public hospitals (DMPHs) are eligible to receive PRIME California Medi-Cal 2020 Demonstration

Approved December 30, 2015 through December 31, 2020

Ammended March 2, 2016
incentive payments (hereinafter “participating PRIME entities”), subject to each DPH system and DMPH submitting a completed Five-year PRIME Project Plan and approval of that Plan by the state. Multiple DPH systems operating under common government ownership may be considered a single participating PRIME entity, or may submit separate applications and be treated as separate participating PRIME entities. Multiple DMPHs operating under common government ownership may submit separate applications or a single application. DMPHs that are under different government ownership may submit a joint plan for consideration, however, a lead DMPH must be identified.

Funding for this pool will not exceed $7.464 billion in combined federal and state shares of expenditures over a five-year period for DPHs and DMPHs to support reforms for care delivery, provider organization and adoption of APMs. The demonstration will provide up to $1.4 billion annually for the DPHs within the DPH Sub-Pool and $200 million annually for the DMPHs within the DMPH Sub-Pool for the first three years of the demonstration. The respective Sub Pools will then phase down by 10 percent in the fourth year of the demonstration and by an additional 15 percent in the fifth year of the demonstration.

PRIME incentive funds shall be disbursed solely to the DPHs and DMPHs listed on Attachment D as eligible participating PRIME entities in accordance with their approved PRIME Project plans. A specified amount of incentive funding will be available annually to each eligible participating PRIME entity for the project metrics approved for that participating PRIME entity in its PRIME plan. The actual receipt of funds will be conditioned on reporting by the participating PRIME entity of progress towards and achievement of the specified targets approved in the PRIME Project Plan. Aside from early stage process metrics, awards in later years will be based on per beneficiary measures of improvement. Each participating PRIME entity (for multiple DPHs operating under a single PRIME project plan or multiple DMPHs operating under a single PRIME project plan, the combined DPHS or DMPHs are collectively considered the participating PRIME entity) will be individually responsible for performance on its metrics in order to receive its potential incentive funding. The inability of one participating PRIME entity to meet a specified target will not preclude other participating PRIME entities operating under separate PRIME Project Plans from receiving incentive payments for achievement of a target.

IV. PRIME Domains and Projects
PRIME projects are grouped into three domains (listed below), each of which has explicit connection to the achievement of: (a) patient-centered, data-driven, team-based care; (b) point-of-care services, complex care management, population health management driven by electronic health records and data analytic capacity for system-level improvement and culturally competent care; and (c) improved health outcomes as evidenced by clinical, preventable events, and patient
experience metrics. The below three domains represent important themes that drive quality improvement and population health advancement:

**Domain 1: Outpatient Delivery System Transformation and Prevention:** Projects in this domain are intended to achieve major improvements in clinical quality and population health, with a particular focus on ambulatory care redesign, integration of physical and behavioral health, patient safety and prevention. These projects are intended to help make sure that patients experience timely access to high-quality, efficient, and patient-centered care. The menu of projects under this domain includes:

1.1 Integration of Physical and Behavioral Health (required for DPH)
1.2 Ambulatory Care Redesign: Primary Care (required for DPH)
1.3 Ambulatory Care Redesign: Specialty Care (required for DPH)
1.4 Patient Safety in the Ambulatory Setting
1.5 Million Hearts Initiative
1.6 Cancer Screening and Follow-up
1.7 Obesity Prevention and Healthier Foods Initiative

**Domain 2: Targeted High-Risk or High-Cost Populations:** Projects in this domain are focused on specific populations that would benefit most significantly from care coordination and alignment. The menu of projects under this domain includes:

2.1 Improved Perinatal Care (required for DPH)
2.2 Care Transitions: Integration of Post-Acute Care (required for DPH)
2.3 Complex Care Management for High Risk Medical Populations (Required for DPH)
2.4 Integrated Health Home for Foster Children
2.5 Transition to Integrated Care: Post Incarceration
2.6 Chronic Non-Malignant Pain Management
2.7 Comprehensive Advanced Illness Planning and Care

**Domain 3: Resource Utilization Efficiency:** Projects in this domain are designed to reduce ineffective or harmful clinical services and reduce unwarranted variation in the use of evidence-based diagnostics and treatments. The menu of projects under this domain includes:

3.1 Antibiotic Stewardship
3.2 Resource Stewardship: High-Cost Imaging
3.3 Resource Stewardship: Therapies Involving High-Cost Pharmaceuticals
3.4 Resource Stewardship: Blood Products

V. **Key Elements of Five-Year PRIME Project Plans**
PRIME participating DPH systems will implement a minimum of 9 PRIME projects: at least four Domain 1 projects (of which three specific projects are required projects), at least four Domain 2 projects (of which three specific projects are required), and at least one Domain 3 project. PRIME participating DMPHs will implement at least one PRIME project, selected from the Projects and Metrics Protocol (Attachment Q), however, may implement additional projects as approved by the state in the PRIME Plan Application.

PRIME projects will be implemented over the course of five PRIME demonstration years, each corresponding to the state fiscal year from July 1 through June 30 (“PRIME DY”). The first PRIME DY is from July 1, 2015, through June 30, 2016.

No later than one week following the approval of the PRIME protocols, DHCS will provide participating PRIME entities with a standardized Five-year PRIME Project Plan template, consistent with the requirements in STC 75 in Section IX. The plan shall include the following sections:

1. Participating Entity Information
2. Executive Summary of 5-Year Plan that includes a summary of the overall Five-year PRIME Project Plan, a description of the participating PRIME entity and local needs, and goals and objectives for being a high-performing safety net system
3. Narrative on how the Five-year PRIME Project Plan will result in improved care for the patients they serve and a path for sustained delivery system improvement
4. Project Selection
5. Statement of Understanding of Project Metrics
6. Program Incentive Payment Amounts
7. Signed Certification statement attesting that the leadership of PRIME participating entities attests to the accuracy of all PRIME-related information submitted to DHCS.

VI. Plan Review and Approval Process

A. DHCS Plan Approval Process

DHCS will review all Five-year PRIME Project Plans according to the following timeline:

1. By February 1, 2016, or 30 days after the approval of the PRIME protocols (whichever is later), each participating PRIME entity seeking to participate in PRIME will submit the completed Five-year PRIME Pool Plan to DHCS for review.

2. DHCS shall review each plan to verify that it conforms to the below checklist:
a. The plan is in the prescribed format.
b. The plan contains and completes all required elements described herein and is consistent with the STCs.
c. The plan conforms to the requirements for Domains 1, 2 and 3 as described herein, as well as in the Projects and Metrics Protocol (Attachment Q).
d. The amount and distribution of funding is in accordance with Section VII of this protocol “Disbursement of Pool Funds.”

3. By March 15, 2016, or 45 days following the due date for submission of the Five-year PRIME Project Plans, DHCS will complete its review of the plan, and will respond to the participating PRIME entity in writing with any questions, concerns or problems identified.

4. The participating PRIME entity will respond to any of DHCS’ questions and concerns in writing within 3 business days of notification by DHCS.

5. By April 1, 2016, or 60 days following the due date for submission of the Five-year PRIME Project Plans DHCS will take action on all plans, and will approve or disapprove each plan.

B. Plan Modification Process

1. Consistent with the recognized need to provide flexibility for participating PRIME entities to modify their plans over time and take into account evidence and learning from their own experience and from the field, as well as for unforeseen circumstances, no more than once a year, and by June 30th of each PRIME DY, a participating PRIME entity may submit a request to DHCS to modify its plan. The modification shall be effective as of the date approved by DHCS. PRIME Plan modifications are limited to the circumstances described below.

2. Project removals:
   a. Should a participating PRIME entity no longer meet the minimum 30 patient volume criteria, as specified in Projects and Metrics Protocol (Attachment Q), or no longer finds it practical (e.g. from a clinical or operational standpoint) to continue one or more projects in its approved plan, a participating PRIME entity may seek to remove a project:
      i. A DPH system may seek to remove an optional project as long as the minimum requirement of 9 total projects, including the 6 required projects, continues to be met, which may be satisfied through a substitute project in the same domain as necessary.
ii. A DPH system may seek to remove a required project if it meets the Exclusions for Project criteria in the Projects and Metrics Protocol (Attachment Q) at the end of DY 11. A DPH system may seek to remove a required project after DY 11 but only in the case that the DPH system no longer meets the 30 patient volume requirement for that project. If a DPH system removes a required project, it must select another project in the same domain as the project that was removed. A DMPH may seek to remove a project from its plan, as long as it meets the 1 project minimum, or terminate its participation in PRIME.

b. A participating PRIME entity as of the effective date of a project’s removal will forfeit any further funding for that project. The participating PRIME entity system shall retain all incentive payments associated with achievements related to that project prior to the removal of that project.

3. Should a participating PRIME entity undergo significant changes in data sources, such a wholesale implementation of a new electronic health record, a plan modification can be submitted for DHCS approval to change annual targets. In addition, should a participating PRIME entity securing a new Medi-Cal managed care contract that results in a significant increase in the number of assigned lives a plan modification can be submitted for DHCS approval to change annual targets.

4. Requests for modification must describe the basis for the proposed modification. If the participating PRIME entity seeks to replace one project with another, it must indicate this proposed change in the request for modification. The 60-day timeline for DHCS to review that is delineated for the Five-year PRIME Project Plans will apply. In the event that DHCS does not approve a modification to a participating PRIME entity’s plan, the participating PRIME entity may seek redress by requesting a meeting with the DHCS Director to resolve any issues. The meeting shall take place in a timely manner.

C. Metric Modification Process

1. Over the course of the PRIME, participating PRIME entities may request a project metric change. DPHs must submit one request on behalf of all of the DPHs that are implementing projects that include a relevant metric, and DMPHs must submit a request on behalf of all DMPHs on behalf of all DMPHs that are implementing a project that include a relevant metric. Requests must include evidence of concurrence by all other DPHs or DMPHs reporting on the applicable metric.

2. Request for metric changes may be submitted no more than once a year and by June 30th of the Demonstration Year. Requests for metric changes must describe the basis for the
proposed change, the proposed change itself, and the applicable project. Requests may recommend metric substitution or removal.

3. For innovative metrics only (as defined in the PRIME Projects and Metrics Protocol Attachment Q), in addition to substitutions or removal, requests may also recommend metric modification. Metric modification requests will be forwarded to the Measure Steward for review. The Measure Steward may accept or reject the modification request. In the case of acceptance, the modified metric will enter a rigorous testing process (as described in the Metrics and Specifications manual), and if approved for use in PRIME by DHCS, the modified metric will be used in all applicable projects as Pay for Reporting until which time it has been deemed acceptable for Pay for Performance status. Should the modification request be rejected by the Measure Steward, DHCS will review whether or not to continue to use the metric for the specified project.

4. DHCS will seek input from all participating PRIME entities engaged in projects that include the metric in question. The 60 day timeline for DHCS to review that is delineated for the Five-year PRIME Project Plans will apply. In the event that DHCS does not approve the requested metric change, the original metric will remain in use for the specified projects and the participating PRIME entities may seek redress by requesting a meeting with the DHCS Director to resolve any issues. The meeting shall take place in a timely manner.

VII. Allocation and Disbursement of Pool Funds

Subject to the annual limits set forth in the STCs, aggregate incentive payments available over the 5-year demonstration period to a participating entity will be based on the methodology described below.

A. Total Available PRIME Incentive Payments for a DPH Five-Year PRIME Pool Plan

PRIME payments for each participating PRIME entity are contingent on that entity meeting project metrics’ targets in its approved Five-year PRIME Pool Plans.

For PRIME DY 11 only, 25% of the total available PRIME funding will be paid based on the submission and approval of the Five-year PRIME Project Plan, pursuant to STC 100a. The remaining 75% will be paid based on the submission and approval of project baseline data collected through July 1, 2015 – June 30, 2016 in conjunction with the final year-end report. All of the PRIME funding in subsequent DYs will be available as incentive payments based on metric achievement to each DPH system across the three domains. The measurement year for all
metrics will coincide with the applicable demonstration year, and for DY 11, metrics for the baseline year will be measured based on July 1, 2015 – June 30, 2016.

The maximum available PRIME payment amount by PRIME DY by domain under the DPH systems pool is summarized in Table 1 below.

### Table 1: Total Computable PRIME Payments for DPHs

<table>
<thead>
<tr>
<th>$ (total computable)</th>
<th>DY 11</th>
<th>DY 12</th>
<th>DY 13</th>
<th>DY 14</th>
<th>DY 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-Year PRIME Plan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25.0%</td>
<td>350,000,000</td>
<td>0.0%</td>
<td>0</td>
<td>0.0%</td>
<td>0</td>
</tr>
<tr>
<td>Domain 1: System Transformation</td>
<td>37.5%</td>
<td>525,000,000</td>
<td>50.0%</td>
<td>700,000,000</td>
<td>50.0%</td>
</tr>
<tr>
<td>Domain 2: High-Risk Populations</td>
<td>30%</td>
<td>420,000,000</td>
<td>40.0%</td>
<td>560,000,000</td>
<td>40.0%</td>
</tr>
<tr>
<td>Domain 3: Resource Utilization</td>
<td>7.5%</td>
<td>105,000,000</td>
<td>10.0%</td>
<td>140,000,000</td>
<td>10.0%</td>
</tr>
<tr>
<td>Total</td>
<td>100.0%</td>
<td>1,400,000,000</td>
<td>100.0%</td>
<td>1,400,000,000</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

1. Every PRIME metric in a given domain will have an annual base value that is calculated by dividing the annual total available amount of PRIME funds in the domain by the base number of metrics across all projects, which is thirty one for domain 1, twenty-three for domain 2, and four for domain 3. The base number of metrics (31, 23, and 4) are estimated averages based on the number of metrics for each required project by domain, plus the average number of metrics per optional project in each domain. The annual base value per metric by domain and per year is summarized in Table 2 below.

### Table 2: Annual Base Value Per Metric and Domain for DPHs

<table>
<thead>
<tr>
<th>$ (total computable)</th>
<th>DY 11</th>
<th>DY 12</th>
<th>DY 13</th>
<th>DY 14</th>
<th>DY 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domain 1: System Transformation</td>
<td>16,935,484</td>
<td>22,580,645</td>
<td>22,580,645</td>
<td>20,322,581</td>
<td>17,274,194</td>
</tr>
<tr>
<td>Domain 2: High-Risk Populations</td>
<td>18,260,870</td>
<td>24,347,826</td>
<td>24,347,826</td>
<td>21,913,043</td>
<td>18,626,087</td>
</tr>
<tr>
<td>Domain 3: Resource Utilization</td>
<td>26,250,000</td>
<td>35,000,000</td>
<td>35,000,000</td>
<td>31,500,000</td>
<td>26,775,000</td>
</tr>
</tbody>
</table>

2. If the number of projects and metrics within a domain in the DPH system’s Five-Year PRIME Project Plan varies from the applicable base number of 31, 23, or 4, the base
metric value for the domain for the DPH system will be adjusted by multiplying by the following ratio: (base metric number / number of metrics in all projects in domain in approved PRIME Project Plan for given year).

3. The amount of PRIME funding available to a DPH system for each metric will be equal to the base value for each metric, adjusted as necessary in step 2, multiplied by a DPH system-specific proportional allotment factor. The DPH system-specific proportional allotment factor is developed from system-specific data, reflecting each DPH system’s unique number of Medi-Cal beneficiaries treated as well as overall costs incurred for those patients, to reflect the different mixes of services provided and acuities of patient populations treated by different DPH systems participating in PRIME. The DPH system-specific proportional allotment factor is set forth in Table 3 below for each DPH system.

Table 3: Proportional allotment factors

<table>
<thead>
<tr>
<th>Eligible DPH System</th>
<th>Proportional allotment factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>UC Davis Medical Center</td>
<td>0.041738</td>
</tr>
<tr>
<td>UC Irvine Medical Center</td>
<td>0.026019</td>
</tr>
<tr>
<td>UC San Diego Medical Center</td>
<td>0.025031</td>
</tr>
<tr>
<td>UC San Francisco Medical Center</td>
<td>0.031586</td>
</tr>
<tr>
<td>UC Los Angeles Medical Center and Santa Monica UCLA Medical Center</td>
<td>0.018658</td>
</tr>
<tr>
<td>Los Angeles County health system</td>
<td>0.319584</td>
</tr>
<tr>
<td>Alameda Health System</td>
<td>0.045959</td>
</tr>
<tr>
<td>Arrowhead Regional Medical Center</td>
<td>0.061520</td>
</tr>
<tr>
<td>Contra Costa Regional Medical Center</td>
<td>0.053761</td>
</tr>
<tr>
<td>Kern Medical Center</td>
<td>0.045296</td>
</tr>
<tr>
<td>Natividad Medical Center</td>
<td>0.022714</td>
</tr>
<tr>
<td>Riverside University Health System - Medical Center</td>
<td>0.047685</td>
</tr>
<tr>
<td>San Francisco General Hospital</td>
<td>0.048880</td>
</tr>
<tr>
<td>San Joaquin General Hospital</td>
<td>0.028667</td>
</tr>
<tr>
<td>San Mateo County General Hospital</td>
<td>0.029885</td>
</tr>
<tr>
<td>Santa Clara Valley Medical Center</td>
<td>0.085631</td>
</tr>
<tr>
<td>Ventura County Medical Center</td>
<td>0.067386</td>
</tr>
</tbody>
</table>

4. To determine the amount distributed available to DPH systems upon approval of their Five-Year PRIME Project Plan in DY 11, each DPH system must multiply the aggregate amount available contingent on such approval by its own proportional allotment factor in Table 3 above.

B. Total Available PRIME Incentive Payments for a DMPH Five-Year PRIME
PRIME payments for each participating PRIME entity are contingent on that entity meeting project metrics’ targets in its approved Five-year PRIME Pool Plans.

Table 4: Total Computable PRIME Payments for DMPHs

<table>
<thead>
<tr>
<th></th>
<th>DY 11</th>
<th>DY 12</th>
<th>DY 13</th>
<th>DY 14</th>
<th>DY 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>$200,000,000</td>
<td>$200,000,000</td>
<td>$200,000,000</td>
<td>$180,000,000</td>
<td>$153,000,000</td>
</tr>
</tbody>
</table>

1. The maximum available PRIME funding shall be allocated across all DMPH systems as follows:
2. A proportional allotment factor for each DMPH (reflected in Table 5) is using the following factors:
   b. An adjustment factor based on the number of projects undertaken by each DMPH to recognize the diversity among these facilities.
   c. A baseline floor amount of .0075 in recognition of small/rural hospitals and the baseline effort required of any participating entity.
3. The proportional allotment factors were determined using the above factors as follows:
   a. Initially, 80% of the total annual PRIME funding for DMPHs is allocated to each DMPH based on their pro-rata share of total Medi-Cal and uninsured acute net revenue from (2)(a).
   b. The initial remaining 20% of the total annual PRIME funding for DMPHs is divided by the total number of projects projected to be undertaken by participating DMPHs (108) to determine a per project additional amount to recognize the diversity among the facilities and the additional effort of doing multiple projects.
   c. An initial allocation of total annual PRIME funding across the DMPHs is then done by adding the results of (a) and (b).
   d. In order to ensure a baseline floor amount of funding as noted in (2)(a) any DMPH-specific allocation determined in (c) that would result in an allocation factor below .0075 is adjust to achieve the baseline floor allocation equal to the .0075 allotment factor.
   e. The remaining DMPHs not adjusted to achieve the baseline floor of .0075, are adjusted on a pro-rata basis so as to not exceed the total funding available.
   f. The resulting allocations after the adjustments in (e) and (f) are then converted into proportional allotment factors by dividing the individual allocation amount by the total PRIME funding for all DMPHs. Table 5 represents the final proportional allotment factors.
Table 5: Proportional allotment factors

<table>
<thead>
<tr>
<th>Eligible DMPH</th>
<th>Proportional allotment factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antelope Valley Hospital</td>
<td>0.1193</td>
</tr>
<tr>
<td>Bear Valley Community Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Coalinga Regional Medical Center</td>
<td>0.0075</td>
</tr>
<tr>
<td>Eastern Plumas Health Care</td>
<td>0.0075</td>
</tr>
<tr>
<td>El Camino Hospital</td>
<td>0.0234</td>
</tr>
<tr>
<td>El Centro Regional Medical Center</td>
<td>0.0453</td>
</tr>
<tr>
<td>Hazel Hawkins Memorial Hospital</td>
<td>0.0131</td>
</tr>
<tr>
<td>Healdsburg District Hospital</td>
<td>0.0113</td>
</tr>
<tr>
<td>Jerold Phelps Community Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>John C. Fremont Healthcare District</td>
<td>0.0075</td>
</tr>
<tr>
<td>Kaweah Delta Health Care District</td>
<td>0.1579</td>
</tr>
<tr>
<td>Kern Valley Healthcare District</td>
<td>0.0075</td>
</tr>
<tr>
<td>Lompoc Valley Medical Center</td>
<td>0.0285</td>
</tr>
<tr>
<td>Mammoth Hospital</td>
<td>0.0116</td>
</tr>
<tr>
<td>Marin General Hospital</td>
<td>0.0122</td>
</tr>
<tr>
<td>Mayers Memorial Hospital District</td>
<td>0.0075</td>
</tr>
<tr>
<td>Mendocino Coast District Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Modoc Medical Center</td>
<td>0.0075</td>
</tr>
<tr>
<td>Northern Inyo Hospital</td>
<td>0.0198</td>
</tr>
<tr>
<td>Oak Valley Hospital District</td>
<td>0.0178</td>
</tr>
<tr>
<td>Palo Verde Hospital</td>
<td>0.0175</td>
</tr>
<tr>
<td>Palomar Medical Center (Includes both Palomar Medical Center and Pomerado Hospital)</td>
<td>0.1010</td>
</tr>
<tr>
<td>Pioneers Memorial Healthcare District</td>
<td>0.0308</td>
</tr>
<tr>
<td>Plumas District Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Salinas Valley Memorial Healthcare System</td>
<td>0.0509</td>
</tr>
<tr>
<td>San Bernardino Mountains Community Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>San Gorgonio Memorial Hospital</td>
<td>0.0175</td>
</tr>
<tr>
<td>Seneca Healthcare District</td>
<td>0.0075</td>
</tr>
<tr>
<td>Sierra View District Hospital</td>
<td>0.0470</td>
</tr>
<tr>
<td>Sonoma Valley Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Sonoma West Medical Center</td>
<td>0.0075</td>
</tr>
<tr>
<td>Southern Inyo Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Tahoe Forest Hospital District</td>
<td>0.0085</td>
</tr>
<tr>
<td>Tehachapi Valley Healthcare District</td>
<td>0.0075</td>
</tr>
<tr>
<td>Tri-City Medical Center</td>
<td>0.0702</td>
</tr>
<tr>
<td>Trinity Hospital</td>
<td>0.0075</td>
</tr>
<tr>
<td>Tulare Regional Medical Center</td>
<td>0.0306</td>
</tr>
<tr>
<td>Washington Hospital Healthcare System</td>
<td>0.0382</td>
</tr>
</tbody>
</table>
4. To determine the amount available to the DMPH upon approval of their Five-Year PRIME Project Plan in DY 11, each DMPH must multiply the aggregate annual amount available to all DMPHs by its own proportional allotment factor in Table 5 above.

5. Total available PRIME payments for each DMPH are allocated as follows:
   
a. In DY 11 only, 25% of the total available PRIME funding will be paid based on the submission and approval of the Five-year PRIME Project Plan, pursuant to STC 100a.
   
i. For DMPHs requiring infrastructure building metrics that are approved in the Prime Project Plan, the remaining 75% will be based on the achievement of the approved DY11 infrastructure building metrics for the DMPH through the final year-end report. The annual base value for each infrastructure building metric shall be calculated by dividing the value of the remaining 75% by the number of infrastructure building metrics in the DMPH’s approved PRIME Project Plan.
   
   ii. For DMPHs not requiring infrastructure building metrics, the remaining 75% will be based on the submission and approval of project baseline data, through the final year-end report.

6. In DY 12 only:
   
a. For DMPHs requiring infrastructure building metrics that are approved in the PRIME Project Plan:
   
i. Up to 40% of the total PRIME funding will be based on the achievement of the approved DY 12 infrastructure building metrics through the mid-year and final year-end report. The annual base value for each infrastructure building metric shall be calculated by dividing the value of the infrastructure building funding percentage by the number of infrastructure building metrics in the DMPH’s approved PRIME Project Plan.
   
   ii. The remaining 60% or more will be available as incentive payments based on the metric achievement. The annual base value for each metric shall be calculated by dividing the value of the remaining percentage by the number of metrics in the DMPH’s approved PRIME Project Plan.

b. For DMPHs not requiring infrastructure building metrics, all of the PRIME funds will be available as incentive payments based on the metric achievement. The annual base value of each metric shall be calculated by dividing the total DY12 PRIME Project Plan funding for the DMPH by the number of metrics across all the projects included in the DMPH’s approved PRIME Project Plan.
7. For DYs 13-15: All of the PRIME funds will be available as incentive payments based on metric achievement to each DMPH as contained in their PRIME Project Plan.
   a. Each DMPH’s PRIME metric will have an annual base value which is calculated by dividing the annual total PRIME Project Plan funding for the DMPH by the number of metrics across all the projects included in the DMPH’s approved PRIME Project Plan.

C. Payment Based on Metric Target Achievement

1. Each participating PRIME entity will be individually responsible for performance on its metrics in order to receive its potential incentive funding from the relevant Sub-Pool. Every 6 months, participating PRIME entities will be able to receive incentive payments related to performance on metrics, as specified below.

2. In order to receive incentive funding, the participating PRIME entity must submit the required Mid-Year Report and Final Year-End Report as described in this Attachment.

3. Incentive payments are calculated separately for each metric. The amount of the incentive funding paid to a participating PRIME entity will be based on the amount of progress made on each specific metrics, and the incentive payment amounts associated with those metrics as determined in Sections A & B above and contained in the entity’s Prime Project Plan.

4. Calculating Achievement Values
   a. Pay-for-Reporting Project (P4R) Metrics: Progress for a metric target will be categorized as fully achieved or not achieved. As an interim payment, the DPH or DMPH is eligible to receive 50% of the metric value for a P4R metric if reported in the Mid-Year Report. The DPH or DMPH may earn the full incentive amount for reporting a P4R metric in the Final Year-End Report.
   b. Pay-for-Performance Project Metrics: The amount of the incentive funding paid to a participating PRIME entity will be based on the amount of progress made toward achieving its performance target on the standard metric. Based on the progress reported, Tables 6 and 7 will be used to determine the achievement value for metrics with established 90th percentile and 25th percentile benchmarks, which comprise a significant majority of standard metrics. Tables 8 and 9 will be used to determine achievement value for metrics with established benchmarks but without 90th and 25th percentile rankings. Targets for these metrics will be established based on a standard percent improvement relative to a participating PRIME entity prior end-of-year performance. Achievement value for these non-ranked benchmark metrics will be based on the ability of the PRIME entity to close the gap between the prior end-of-year performance and their individual target.
### Table 6: Interim Mid-Year Metric Performance Achievement

<table>
<thead>
<tr>
<th>End of Year Metric Performance in Prior DY</th>
<th>Interim Mid-Year Metric Performance Achievement Values (AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>≥ 90th percentile</strong></td>
<td>AV = 0</td>
</tr>
<tr>
<td></td>
<td>AV = 0.5</td>
</tr>
<tr>
<td><strong>≥ 25th and &lt; 90th percentile</strong></td>
<td>Performance ≤ 90th percentile</td>
</tr>
<tr>
<td></td>
<td>Performance ≥ 90th percentile</td>
</tr>
<tr>
<td><strong>&lt; 25th percentile</strong></td>
<td>Performance ≤ 25th percentile</td>
</tr>
<tr>
<td><strong>Track A:</strong> If gap between performance and 25th percentile is ≥ 10% gap between performance and 90th percentile</td>
<td>Performance ≥ 25th percentile</td>
</tr>
<tr>
<td><strong>Track B:</strong> If gap between performance and 25th percentile is &lt; 10% gap between performance and 90th percentile</td>
<td>Performance ≥ 25th percentile</td>
</tr>
<tr>
<td><strong>&lt; 25th percentile</strong></td>
<td>Performance &lt; 25th percentile or performance ≥ 25th percentile and &lt; 50% of the 10% Gap is closed</td>
</tr>
</tbody>
</table>

### Table 7: Final Year-End Metric Performance Achievement

<table>
<thead>
<tr>
<th>End of Year Metric Performance in Prior DY</th>
<th>Final Year-End Metric Performance Achievement Values (AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>≥ 90th percentile</strong></td>
<td>AV = 0</td>
</tr>
<tr>
<td></td>
<td>AV = 0.5</td>
</tr>
<tr>
<td></td>
<td>AV = 0.75</td>
</tr>
<tr>
<td></td>
<td>AV = 1.0</td>
</tr>
<tr>
<td><strong>≥ 25th and &lt; 90th percentile</strong></td>
<td>Performance ≤ 90th percentile</td>
</tr>
<tr>
<td></td>
<td>Performance ≥ 90th percentile</td>
</tr>
<tr>
<td></td>
<td>≥ 50% to &lt; 75% of the 10% Gap is closed</td>
</tr>
<tr>
<td></td>
<td>≥ 75% to &lt; 99% of the 10% Gap is closed</td>
</tr>
<tr>
<td></td>
<td>100% of the 10% Gap is closed</td>
</tr>
<tr>
<td><strong>&lt; 25th percentile</strong></td>
<td>Performance ≤ 25th percentile</td>
</tr>
<tr>
<td><strong>Track A:</strong> If gap between performance and 25th percentile is ≥ 10% gap between performance and 90th percentile</td>
<td>Performance ≥ 25th percentile</td>
</tr>
<tr>
<td><strong>Track B:</strong> If gap between performance and 25th percentile is &lt; 10% gap between performance and 90th percentile</td>
<td>Performance ≥ 25th percentile</td>
</tr>
<tr>
<td><strong>&lt; 25th percentile</strong></td>
<td>Performance ≤ 25th percentile, Performance &gt; 25th percentile, Performance &gt; 25th percentile</td>
</tr>
<tr>
<td>Final Year-End Metric Performance Achievement Values (AV)</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>End of Year Metric Performance in Prior DY</td>
<td></td>
</tr>
<tr>
<td>AV = 0</td>
<td></td>
</tr>
<tr>
<td>or performance ≥ 25th percentile and</td>
<td></td>
</tr>
<tr>
<td>&lt; 50% of the 10% Gap is closed</td>
<td></td>
</tr>
<tr>
<td>AV = 0.5</td>
<td></td>
</tr>
<tr>
<td>≥ 50% to &lt; 75% of the 10% Gap is closed</td>
<td></td>
</tr>
<tr>
<td>AV = 0.75</td>
<td></td>
</tr>
<tr>
<td>and ≥ 75% to &lt; 99% of the 10% Gap is closed</td>
<td></td>
</tr>
<tr>
<td>AV = 1.0</td>
<td></td>
</tr>
<tr>
<td>closed</td>
<td></td>
</tr>
</tbody>
</table>

Table 8: Interim Mid-Year Metric Performance Achievement for Metrics without National/State Benchmarks

<table>
<thead>
<tr>
<th>Interim Mid-Year Metric Performance Achievement Values (AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AV = 0</td>
</tr>
<tr>
<td>&lt; 50% of the gap between end of year performance and current year target* is closed</td>
</tr>
<tr>
<td>AV = 0.5</td>
</tr>
<tr>
<td>≥ 50% of the gap between end of year performance and current year target* is closed</td>
</tr>
</tbody>
</table>

*DHCS to set a standard percent improvement target relative to individual current annual performance

Table 9: Final Year-End Metric Performance Achievement for Metrics without National/State Benchmarks

<table>
<thead>
<tr>
<th>Final Year-End Metric Performance Achievement Values (AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AV = 0</td>
</tr>
<tr>
<td>&lt; 50% of the gap between end of year performance and current year target* is closed</td>
</tr>
<tr>
<td>AV = 0.5</td>
</tr>
<tr>
<td>≥ 50% to &lt; 75% of the gap between end of year performance and current year target* is closed</td>
</tr>
<tr>
<td>AV = 0.75</td>
</tr>
<tr>
<td>≥ 75% to &lt; 99% of the gap between end of year performance and current year target* is closed</td>
</tr>
<tr>
<td>AV = 1.0</td>
</tr>
<tr>
<td>100% of the gap between end of year performance and current year target* is closed</td>
</tr>
</tbody>
</table>
*DHCS to set a standard percent improvement target relative to individual current annual performance

b. The participating PRIME entity is eligible to receive an amount of incentive funding for the project metric determined by multiplying the total amount of funding related to the metric by the reported achievement value.

c. If a participating PRIME entity has received funding during a previous reporting period for a given metric, only the remaining amount is eligible for funding in the current reporting period.

D. Progress and Payment Reconciliation

If within a given DY a participating PRIME entity has reported progress on a metric in an interim mid-year report and received partial funding based on that reported mid-year performance, only the remaining funding for full performance in the year is eligible to be earned upon submission of the final year-end report that documents the applicable full year metric performance.

If, upon review of the interim mid-year and final year-end reports, it is determined that the progress by the participating PRIME entity had not been achieved as reported and that such progress would have resulted in a lower payment amount, the participating PRIME entity will be required to re-pay the federal portion of the overpayment amount. If the review of the report determines that actual progress exceeded the progress previously reported and paid for, and the actual progress would have resulted in increased payment (up to the maximum allocated for the metric), then the participating PRIME entity will be able to receive the appropriate additional payment in conjunction with an updated report subject to the intergovernmental transfer process below.

E. Reporting for Payment

All participating PRIME entities will produce an interim mid-year and final year report on metric progress specific to the participating PRIME entity’s project and its PRIME defined population. The reports shall be submitted using the standardized reporting mechanism approved by DHCS and CMS. The standardized reporting mechanism shall calculate the incentive payment amount being requested for the progress achieved in accordance with the metric achievement values estimated above.

The report must include submission of the data for each of the metrics for which the participating PRIME entity has achieved progress and seeks payment under the PRIME, except that a PRIME entity may provide estimates or reasonable projections if particular data is unavailable due to circumstances beyond the PRIME entity’s control, including data that is collected and maintained by an external entity, such as a managed care organization, which has not been
provided to the participating PRIME entity in a timely and accurate manner. The reports will be due in accordance with the following:

1. **Interim Mid-Year Report**: Reporting on metrics measuring through December 31. The report and request for payment is due March 31, with payment occurring no later than April 30. For PRIME DY 11 only, the submission of the Five-year PRIME Project Plan will constitute the submission of the Interim Mid-Year Report.

2. **Final Year-End Report**: Reporting on metrics measuring through June 30. The report and request for payment is due September 30, with payment occurring no later than October 30. For PRIME DY 11 only, the final year-end report must include the submission of the baseline data and a narrative that describes the source of this information, the reporting infrastructure, how it was developed, and how this data will serve as the basis for improvement over the remaining Demonstration.

The Measurement Period for Mid-Year and Final Year-End Reports is listed in the Projects and Metrics Protocol (Attachment Q).

The State must use this documentation in support of PRIME claims made on the MBES/CBES 64.9 Waiver form.

### F. Intergovernmental (IGT) Transfer Process

DHCS will issue requests to the entities for intergovernmental transfer amounts necessary for the nonfederal share of the applicable incentive payment amounts, and within the timeframe necessary for the payments to be paid by the dates specified in E(1) and E(2) above. A DPH or DMPH, or its affiliated public agencies, will make an intergovernmental transfer of funds to DHCS in the amount specified within 7 days of receiving the DHCS request. Upon timely receipt of the intergovernmental transfers, DHCS will draw the federal funding and pay both the non-federal and federal shares of the payment to DPHs or DMPHs as applicable. In the event of any misreported or insufficient data, DHCS will not be bound to the 30 day payment timelines in E(1) and E(2), as otherwise applicable, with respect to a participating PRIME entity until its reports are adequately corrected for approval for payment.

### VIII. STATE REVIEW PROCESS

Hospital payments will be initiated by the submission of complete reports. DHCS will conduct an initial review of all submitted reports for data completeness. If reports are complete, DHCS will issue IGT letters consistent with the timeframe for payment described above. DHCS will then conduct the administrative and clinical reviews, as outlined below, and will adhere to Progress and Payment Reconciliation Procedures as outlined in section VII.B above. The reviews consist of the following:
1. **Administrative Review:** DHCS will conduct an administrative review of the reports for technical and administrative issues using guidelines approved by CMS.

   *Clinical Review:* DHCS will conduct a review of the reports for clinical issues using the guidelines approved by CMS.

2. Reviews will be issued to participating PRIME entities. The PRIME entities will be given up to fourteen (14) calendar days to respond to issues and to revise reports as needed.

3. DHCS will review revisions and will coordinate any further revisions with the participating PRIME entity.

**IX. Reinvestment of Unallocated Funds**

Notwithstanding the annual limits set forth in the STCs, participating PRIME entities will have the opportunity to recapture unused or unclaimed PRIME pool payments:

**A. Unused Pool Fund**

1. If, through the PRIME Project plan submission and approval process, there is Pool funding that remains unallocated pursuant to Section VII.A and B. above, then the affected participating PRIME entity, in addition to all other participating PRIME entities, may implement additional projects or demonstrate greater performance that will be applicable to the remaining Demonstration Years to earn the unused funds.

2. The opportunity to submit earn additional funding will be offered and allocated first to the affected participating PRIME entity, then to participating PRIME entities within the same Sub Pool, then among participating PRIME entities in the same Pool.

3. Requests for additional projects must be approved by the state.

**B. Unclaimed Pool Payment**

1. As set forth in section VII C. above, pay-for-performance metrics have annual pay-for-performance targets with an identified quantitative achievement target set at the beginning of each demonstration year. Pay-for-performance metrics will earn incentive payments proportional to the achievement value on a percentage basis, whereas pay-for-reporting
metrics do not have a quantitative achievement target, and thus may only earn the full incentive payment value based on submission of the metric report.

2. If, at the end of the DY, a pay-for-performance project metric target is not met by a participating PRIME entity and that entity is not able to fully claim funds that otherwise would have been earned for meeting the metric target (“unearned funds”), a participating PRIME entity shall have the opportunity to claim such unearned funds through the following mechanisms. This 90% limitation applies to the aggregate amount of unearned funds that can be reclaimed through the mechanisms described in both IX.B.2.a. and IX.B.2.b.
   a) Within a PRIME DY, participating PRIME entities can reclaim up to 90% of any unearned funds on pay-for-performance metrics by over performing (exceeding the target) in other pay-for-performance metrics in any PRIME project in that same demonstration year.
      (1) Over-performance must be demonstrated by exceeding other project metric targets by at least 50% or greater.
      (2) Table 9: Unearned Claiming (for current DY) demonstrates the amount of unearned funds that can be claimed through over-performance on pay-for-performance on a metric. The total amount of unearned funds that can be claimed by a participating PRIME entity will be proportional to the amount of over performance on all other pay for performance metric targets in the aggregate.

<table>
<thead>
<tr>
<th>End of Year Metric Performance</th>
<th>Amount of unearned funds that are eligible for re-claiming</th>
</tr>
</thead>
<tbody>
<tr>
<td>50-74% over performance</td>
<td>25% of the metric value</td>
</tr>
<tr>
<td>75%-99% over performance</td>
<td>37.5% of the metric value</td>
</tr>
<tr>
<td>100% over performance</td>
<td>50% of the metric value</td>
</tr>
</tbody>
</table>

(3) Participating PRIME entities are eligible to claim up to 90% of the amount of its total unearned funds based on the aggregate value of the over performance on the other metrics.

(4) The remaining 10% of unearned PRIME funds will be withheld and will be included in the DPH or DMPH PRIME High Performance Pool, described
in (c) below. Unearned PRIME funds from DPHs will be included in the DPH High Performance Pool and unearned PRIME funds from DMPHs will be included in the DMPH High Performance Pool.

(5) When participating PRIME entities submit their year-end reports, they must indicate which, if any, metrics they have not fully met and have unearned funds, and which metrics they have over-performed and are being used to claim such unearned funds.

b) If a participating PRIME entity is not able to earn the full 90% value of its unearned funds through the mechanisms set forth in paragraph a. above, the participating PRIME entity will have another opportunity to earn and claim the remainder up to 90% of unearned funds during the subsequent demonstration year on any unmet pay-for-performance metric by demonstrating over-performance on the same unmet metric in the following manner:

(1) Over-performance must be demonstrated by exceeding an unearned funds metric demonstration year target by a minimum of 50% or greater.

(2) The proportion of unearned funds from a given metric that can be claimed will be based on the percentage of over-performance on that same metric. Table 10: Unearned Claiming (for subsequent DY) below demonstrates the amount of unearned funds that can be claimed through over-performance on pay-for-performance metrics.

Table 10: Unearned Claiming (for subsequent DY)

<table>
<thead>
<tr>
<th>End of Year Metric Performance</th>
<th>Amount of the same metric’s prior year’s unearned funds that are eligible for re-claiming</th>
</tr>
</thead>
<tbody>
<tr>
<td>50-74% over performance</td>
<td>25% of a metric’s unearned funds</td>
</tr>
<tr>
<td>75%-99% over performance</td>
<td>37.5% of a metric’s unearned funds</td>
</tr>
<tr>
<td>100% over performance</td>
<td>50% of a metric’s unearned funds</td>
</tr>
</tbody>
</table>

(3) If a participating PRIME entity experiences two consecutive years of not meeting the applicable annual targets for a metric, it will no longer be eligible
for any over-performance reclaiming in that demonstration year or subsequent demonstration year for that metric.

(4) When a participating PRIME entity submits its year-end final report, it must indicate which, if any, over performance metrics are being used to reclaim funds on prior unmet targets for those same metrics.

c) If, through the above mechanisms set forth above in paragraph a. and b. above a participating DPH system or DMPH is not able to claim 90% of their unearned funds from the prior year, any remainder of the 90% of unearned funds for that metric from DPH systems shall be available to be earned by any DPH system through the establishment of a DPH PRIME High Performance Pool and any remainder of the 90% of unearned funds for that metric from DMPHs shall be available to be earned by any DMPH through the establishment of a DMPH PRIME High Performance Pool. The High Performance Pools will also include the 10% withhold of unearned funds referenced in (a) above for the respective DPHs and DMPHs separately.

(1) The DPH High Performance Pool

(a) The DPH PRIME High Performance Pools will be available annually for DY 13 through DY 15 for any DPH system achieving high performance (defined as achieving ≥90th percentile benchmark performance or 20% gap closure) in any of the eligible 19 National Quality Forum (NQF) metrics in the six DPH required PRIME projects.

(b) Eligible metrics in the PRIME High Performance fund do not include any metrics for which a DPH system used to reclaim unearned PRIME funds through mechanisms IX.B.2.a. and b. above.

(c) DPH PRIME High Performance Pool funds shall be allocated on a pro rata basis to each eligible DPH system, based on the value of each DPH system’s eligible NQF metrics for which they have achieved high performance (herein referred to as “high performance metrics”), the aggregate of those values and the total amount of funding available in the pool.

i. Should the total remaining prior year unearned funds from all the DPH systems exceed the aggregate value of all DPH systems’ high performance metrics, all DPH systems will be paid the full value of each of their high performance metrics.

ii. Should the total remaining prior year unearned funds from all the DPH systems be less than the aggregate value of all DPH systems’ high performance metrics, all DPH systems will be paid a proportion of the full value of each of their high performing metrics. That proportion of funds will be equal to the ratio of the total remaining prior year unearned funds and the aggregate value of all DPH systems high performance metrics.
(d) For DY 13, the DPH High Performance Pool includes the DY 12’s remaining of the 90% unearned DPH funds (after application of the mechanisms described in IX.B.2.a and b above) and the 10% withhold described in IX.B.2.a.4 above for DY 12 and DY 13. For DY 14, the DPH High Performance Pool includes the DY 13’s remaining of the 90% unearned DPH funds (after application of the mechanisms described in IX.B.2.a and b above) and the 10% withhold described in IX.B.2.a.4 above for DY 14. For DY 15, the DPH High Performance Pool includes DY 14’s remaining of the 90% unearned DPH funds (after application of the mechanisms described in IX.B.2.a and b), DY 15’s remaining of the 90% unearned DPH funds (after application of the mechanism described in IX.B.2.a), and the 10% withhold for DY 15. The DPH High Performance Pool for each DY does not carry over to the next DY.

(e) When participating DPH PRIME entities submit their year-end final reports, they must indicate which, if any, eligible NQF metrics were used to claim funds from the DPH High Performance Pool.

(2) The DMPH High Performance Pool
   (a) The DMPH PRIME High Performance Pools will be available annually for DY 13 through DY 15 for any DMPH achieving high performance (defined as achieving ≥90th percentile benchmark performance or 20% gap closure) in any of the eligible 19 National Quality Forum (NQF) metrics in the following projects as numbered in Attachment Q: Project 1.1, 1.2, 1.3, 2.1, 2.2 or 2.3.

   (b) Eligible metrics in the PRIME High Performance fund do not include any metrics for which a DMPH used to reclaim unearned PRIME funds through mechanisms IX.B.2.a. and b. above.

   (c) DMPH PRIME High Performance Pool funds shall be allocated on a pro rata basis to each eligible DMPH, based on the value of each DMPH’s eligible NQF metrics for which they have achieved high performance (herein referred to as “high performance metrics”), the aggregate of those values and the total amount of funding available in the pool.

   iii. Should the total remaining prior year unearned funds from all the DMPHs exceed the aggregate value of all DMPHs’ high performance metrics, all DMPHs will be paid the full value of each of their high performance metrics.

   iv. Should the total remaining prior year unearned funds from all the DMPHs be less than the aggregate value of all DMPHs’ high performance metrics, all DMPHs will be paid a proportion of the full value of each of their high performing metrics. That proportion
of funds will be equal to the ratio of the total remaining prior year unearned funds and the aggregate value of all DMPH high performance metrics.

(d) For DY 13, the DMPH High Performance Pool includes the DY 12’s remaining of the 90% unearned DMPH funds (after application of the mechanisms described in IX.B.2.a and b above) and the 10% withhold described in IX.B.2.a.4 above for DY 12 and DY 13. For DY 14, the DMPH High Performance Pool includes the DY 13’s remaining of the 90% unearned DMPH funds (after application of the mechanisms described in IX.B.2.a and b above) and the 10% withhold described in IX.B.2.a.4 above for DY 14. For DY 15, the DMPH High Performance Pool includes DY 14’s remaining of the 90% unearned DMPH funds (after application of the mechanisms described in IX.B.2.a and b), DY 15’s remaining of the 90% unearned DMPH funds (after application of the mechanism described in IX.B.2.a), and the 10% withhold for DY 15. The DMPH High Performance Pool for each DY does not carry over to the next DY.

(e) When participating DMPH PRIME entities submit their year-end final reports, they must indicate which, if any, eligible NQF metrics were used to claim funds from the DMPH High Performance Pool.

X. Learning Collaboratives

As part of this demonstration, DHCS will work in collaboration with participating PRIME entities to support regular learning collaboratives, which will be a required activity for all participating PRIME entities, and may be organized by the goals of PRIME or by the specific PRIME projects as described in the PRIME Funding and Mechanics Protocol (Attachment II). Learning collaboratives are forums for participating PRIME entities to share best practices and get assistance with implementing their PRIME projects. Learning collaboratives should primarily be focused on learning (through exchange of ideas at the front lines) rather than teaching (i.e. large conferences), but DHCS should coordinate with participating PRIME entities to organize at least one face-to-face statewide collaborative meeting a year. Learning collaboratives should be supported by a web site to help participating PRIME entities share ideas and simple data over time (which should not need to be developed from scratch). In addition, the collaboratives should be supported by individuals with training in quality improvement who can answer practical questions about implementation and harvest good ideas and practices that they systematically spread to others. Participating PRIME entities shall fund the non-federal share to support the conducting and operations of learning collaboratives.